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ABSTRACT 
 
SUDHA R. RAMAN: Prescription patterns and injury risk among children with 
attention deficit hyperactivity disorder in the UK 
(Under the direction of Stephen W. Marshall) 
 
The long-term effectiveness of pharmacotherapy for attention deficit 
hyperactivity disorder (ADHD) may be compromised by poor adherence to 
medication.  Children with ADHD experience high rates of injuries and stimulant 
medication use is hypothesized to decrease injury risk by reducing symptoms.  
Longitudinal population-based primary health care data was used to 1) 
describe the initial pharmacological treatment patterns among children with 
ADHD and independent predictors of persistence with initial ADHD treatment and 
2) assess the association between stimulant medication (such as 
methylphenidate) and risk for injury among children with ADHD. 
Children diagnosed with ADHD at age 1-18 between 1994 and 2008 were 
selected from The Health Improvement Network (THIN) database to form the 
overall study group (n=4234). Prescription patterns were described among 1314 
children treated with medication.  The association between child, clinical and 
treatment factors and medication persistence (defined as initial treatment length 
> 6 months) was estimated using binomial regression.  A self-controlled case 
series design was conducted among 328 children who experienced an incident 
injury event and received at least 1 stimulant medication prescription.  Incident 
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rate ratios (IRR) and 95% confidence intervals (CI) for injury comparing periods 
of stimulant medication treatment with untreated periods were estimated using 
conditional Poisson regression. 
Only 35.3% (n=464) of children were persistent with treatment. Children 
initially prescribed long-acting methylphenidate were more likely to persist with 
treatment as compared to standard methylphenidate (Risk Ratio= 1.2; 95% 
Confidence Interval (CI): 1.1, 1.4).  Injury rates were lower during periods of 
stimulant medication use as compared with untreated periods (IRR= 0.70; 
95%CI: 0.52, 0.93).  The association was clearly apparent for males and did not 
decline with increasing time on treatment. 
Conclusions: The majority of children prescribed medication for ADHD do not 
continue on initial treatment for more than 6 months.  Evaluation of the effects of 
ADHD medication in both clinical and research settings should consider the 
observed poor persistence with pharmacological treatment.  Periods of stimulant 
medication use were associated with a decreased risk of injury among children 
treated for ADHD.  Injury risk should be considered in decision-making about 
stimulant medication use among children with ADHD who have been previously 
treated. 
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I. INTRODUCTION 
Attention Deficit Hyperactivity Disorder (ADHD) is increasingly recognized as a 
significant public health concern that affects 5% of school-aged children 
worldwide.[1,2]  Characterized by core symptoms of hyperactivity, impulsivity and 
inattentiveness, ADHD is associated with academic difficulties, family dysfunction, 
poor peer relationships, substance abuse and psychiatric comorbidities in 
childhood[3-5] and across the lifespan.[6]  
The effectiveness of pharmacotherapy (primarily stimulant medication) for short-
term ADHD symptom reduction is well established.[7,8]  The evidence for the long-
term effectiveness of medication on symptoms and ADHD-associated academic and 
psychosocial outcomes is less compelling potentially due to the lack of consistent 
and timely medication use in this population.[9,10]  Poor ‘adherence’, broadly 
defined as the extent to which a person’s behavior, including taking medication, 
corresponds with agreed recommendations from a health care provider[11] is 
common among children with ADHD in the United States (US).[12]  Measures of 
overall ADHD medication adherence and ADHD medication persistence (defined as 
the amount of time on regular and consistent drug therapy[13]) are associated with 
child-related factors (such as age, gender and disease severity,[14,15]) parental 
factors (such as beliefs about pharmacological treatment[10]) and treatment factors 
(such as type and dose of medication and side effects[16]).  The identification of 
 2
these factors may help clinicians identify children who are more or less likely to 
continue with treatment.  Research is required to understand the extent of poor 
treatment persistence and identify children who may not be fully benefiting from 
treatment.  
Children with ADHD experience high rates of injuries, including fractures, head 
injury and burns.[17-19]  While stimulant medications for the treatment of ADHD 
such as methylphenidate (MPH) have been shown to reduce core symptoms and 
improve both school performance and family interactions[20] it is unclear if treatment 
also affects injury risk. 
Stimulant medication use is hypothesized to decrease injury risk by reducing 
ADHD symptoms, such as inattention or impulsivity.  Conversely, periods of 
medication non-use may result in a rise in ADHD symptoms, increasing risk for injury 
by compromising a child’s ability to evaluate potential dangers in the environment 
and react appropriately.[21-24]  Previous clinical trials have reported too few injuries 
to evaluate these hypotheses.[25]  Previous observational research that compared 
two groups of children by the type or amount of exposure to stimulant medication 
provided some evidence for a protective effect of medication on injury rates,[16,26] 
however unmeasured differences, such as ADHD severity or level of parental 
supervision, between groups of children who were being compared may have 
confounded these findings.  The existing research to date has not considered 
additional aspects of the association between injury and stimulant medication, such 
as the comparison of injury rates for children with ADHD during periods on and off 
medication, the injury rates preceding medication initiation, or the possibility that 
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medication may have a time-varying effect over the course of a treatment period. 
The research described in this dissertation addresses these two research gaps 
within a large longitudinal population-based primary care database by 1) describing 
the initial pharmacological treatment patterns among UK children with ADHD and 
evaluating independent predictors of persistence with initial ADHD treatment and 2) 
assessing the association between stimulant medication and risk for injury among 
children with ADHD by comparing rates for injury during periods of stimulant 
medication treatment with untreated periods using methods to decrease confounding 
by inter-individual differences.
  
 
II. REVIEW OF LITERATURE 
A. BACKGROUND 
Public health significance of attention deficit hyperactivity disorder 
Attention deficit hyperactivity disorder (ADHD) is increasingly recognized as a 
significant public health concern.[1]  Despite the importance of this issue, measuring 
the prevalence of ADHD has been challenging.   Epidemiological studies are often 
hampered by lack of a consistent case definition.  In general, estimates of the ADHD 
prevalence in school-age children range between 3% and 5% in the US, where more 
inclusive diagnostic criteria tend to be used, and between 1.3% and 4% in the United 
Kingdom (UK) and Europe where ADHD is typically more stringently 
defined.[1,27,28]  The diagnosis of ADHD requires a pattern of problematic 
behavior, characterized by core symptoms of inattention, hyperactivity and 
impulsivity, be present more frequently than other children at the same level of 
development and that the behaviors are seen in more than one setting (i.e. home 
and school).[29]  ADHD is more commonly diagnosed in males than females.  
Diagnosis rates peak in the school-age years (ages 6 to 10).[30]  ADHD is 
associated with a range of limitations, including school functioning (e.g. classroom 
disruptions and poor achievement), problems with adult relationships (e.g. non-
compliance with teacher and parent requests) and relationships with peers and 
siblings (e.g. intrusive behaviors).[27]  The most effective interventions for ADHD are 
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medication and psychosocial/behavioral treatments such as parent training and 
adapted education programming; these both require coordination and resources 
from the health care and educational systems.[31]  Additionally, children with ADHD 
are at risk for other comorbid conditions (e.g. learning disabilities, anxiety disorders 
and conduct disorders), substance abuse and poor adolescent driving 
behavior.[4,5,32]  Though some ADHD symptoms may abate as children grow older, 
the long-term effects of suboptimal development due to ADHD symptoms have been 
reported in adulthood (e.g. family and peer relationships, self-esteem, academic 
achievement and employment status).[6,33]  Therefore, in addition to the impact on 
children’s development, social and economic costs of ADHD across the health, 
education and criminal justice systems are substantial.[31]  The extent and range of 
poor outcomes over childhood, adolescence and adulthood underscores the 
importance of timely diagnosis and effective treatments in order to minimize the 
pervasive effects of this disorder.  
Public health significance of childhood injury  
Injury is a leading cause of death and disability worldwide among children.[34]  
For every child death due to injury in the US, there are an estimated 45 
hospitalizations and 1300 emergency room visits.[35]  At the primary care level, 
children with injuries constitute about 10 to 15% of visits to general 
practitioners.[36,37]  One in four children in the US is injured each year and non-
fatal injuries are a common cause of school absences.[38]  Injuries of a more 
serious nature can affect the physical and emotional development of a child and lead 
to ongoing health issues or disability in addition to requiring substantial health care 
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resources.[39]   
Behavioral risk factors for childhood injury  
There are many individual and community factors that interplay in the 
occurrence of childhood injury.  Family factors, such as socioeconomic status and 
parenting style, and environmental factors, such as neighborhood safety and traffic 
patterns, interact with child characteristics to determine injury risk.[40]  Child 
characteristics such as gender, age, personality and behavior influence exposure 
and responses to injury hazard. Boys are at higher risk for injury across all ages, 
likely as a result of exposure to injury hazards and increased levels of risk-taking 
behavior.[40,41]  Childhood injury rates and types of injury vary by age, partially as a 
function of physical and cognitive developmental stage, as well as the changing 
activities, environment and supervision of children over the childhood years.  Overall 
injury rates are highest among children ages 1 to 2 years, gradually drop in the 
preschool years (age 3 to 5 years) and then steadily rise with age until 
adolescence.[41]  Types of injury also vary over the developmental course.   For 
example, poisonings and intracranial injuries are most common in young 
children,[42] upper limb fractures are more common in children 6 to 9 years[41] and 
sport injuries, such as concussion and sprains, frequently occur among 
adolescents.[43]   
Other individual-level factors such as cognitive ability, personality, and behavior 
are thought to interact with environment factors to influence how children are able to 
respond to potentially injurious situations.[44]  Behavioral characteristics such as 
activity level, aggression, hyperactivity, poor inhibitory control and impulsivity are 
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acknowledged as important risk factors for injuries to children of all ages.[45-47]   
ADHD as a risk factor for childhood injury 
Children with behavioral conditions such as ADHD, with a combination of these 
three main traits (i.e. hyperactivity, inattention and impulsivity) are at about a two-
fold increased risk for injury as shown in various cross-sectional and nationally 
representative surveys in the UK and North America.[17-19]  Children with ADHD 
experience different types of injuries, as suggested by studies that have examined 
groups of injured children. Discala et al. used data from the US National Pediatric 
Trauma registry and found that injuries among children with a diagnosis of ADHD 
were more likely to be serious injuries, self-inflicted injuries or pedestrian injuries 
than those without ADHD.[48]  Behavioral conditions such as ADHD have also been 
associated with head injury, burns, fractures, poisonings, dental injuries, pedestrian 
injuries and intentional injuries such as self-harm, suicide attempts and injuries from 
assaults.[49-54]  Multiple injuries and more severe injuries are also more common 
among children with ADHD.[48,50,55]   
The mechanism of how ADHD increases injury risk is multifaceted.  First, the 
very nature of hyperactivity, defined as a higher than normal level of activity, may 
increase exposure to situations that have injury risk.[56]  Second, ADHD symptoms 
may be linked to difficulties evaluating potential dangers in the environment, 
estimating physical ability and reacting appropriately.[23,24]  Children with ADHD 
are also likely to have other disorders, such as conduct disorder or oppositional 
behavior disorder, which may independently increase injury risk.[57,58]  Finally, in 
adolescence, ADHD may lead to different social and developmental trajectories that 
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increase risk for injury, including engagement in various risk behaviors such as 
drinking or substance abuse.[59] The above factors may form part of the causal 
pathway between ADHD and injury risk.  
 
B. PATTERNS OF ADHD MEDICATION USE 
The role of medication in the management of ADHD  
Medications, in particular central nervous system stimulants, are commonly 
prescribed as the first line of pharmaceutical treatment for ADHD.[60]  Clinical 
guidelines in both the UK and the US state that there is strong evidence for the use 
of stimulant medication for the treatment of ADHD.[7,61]  Stimulant medications 
such as methylphenidate (MPH) are a widely used treatment for ADHD and have 
been extensively assessed in terms of impact on the core symptoms of ADHD (i.e. 
hyperactivity, impulsivity and inattention), school performance and family 
interactions.[20,62,63]  Stimulant medications act relatively quickly, with 
effectiveness occurring within 60 minutes and lasting up to 12 hours for the newer 
long-acting formulations.[64]  Medication may have longer-term effects on academic 
performance and peer and family interactions by indirect mechanisms, such as the 
facilitation of successful participation in school and family activities.[65]   
Clinically meaningful benefits occur for about 80% of children who are 
prescribed stimulant medication.[20]  The remainder of patients may not respond 
positively due to side effects (such as inhibition of sleep and appetite) or a lack of 
efficacy.  Non-stimulant medications approved for use for ADHD (such as 
atomoxetine) have been found to have treatment effects comparable to standard 
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formulations of MPH but are less effective than long-acting MPH.[66]  Other non-
stimulants are used as second- or third-line alternatives (e.g. alpha-agonists such as 
clonidine and guanfacine, and  antidepressants such as imipramine and 
bupropion).[64,67]   
Adherence and persistence with ADHD medication treatment   
The efficacy of pharmacotherapy (primarily stimulant medication) for short-term 
ADHD symptom reduction is well established,[7,8] however research about the long-
term effectiveness of medication is less compelling.[68]  Treatment guidelines 
suggest that ADHD should be treated with a combination of behavior therapy, 
parental training and pharmacotherapy[65] with medication use for as long as 
clinically effective.[69]  Adherence is a general term that refers to the extent to which 
a person’s behavior, including taking medication, corresponds with agreed 
recommendations from a health care provider.[11]  Although estimates of ADHD 
treatment adherence vary depending on the time period assessed and 
measurements used, overall poor adherence has been found to be very common 
among children with ADHD in United States (US) populations, ranging from 13% to 
64%.[12]   
Within the relevant literature, prospective studies about ADHD medication 
adherence have been generally conducted with clinical trial or recruited patient 
populations.[12]  In contrast, population-based retrospective studies using 
prescription or claims data have yielded estimates of medication persistence, one of 
many measures of adherence. Medication persistence, is defined as the amount of 
time on regular and consistent drug therapy.[13]  Table 2.1 summarizes select 
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studies that use administrative data to assess medication adherence and 
persistence for children with ADHD.  Terminology and measures used to describe 
medication adherence varies greatly between studies, therefore research that 
describe the concepts of ‘compliance’ and ‘continuity’ are also included. 
The majority of the reviewed literature assesses stimulant medication use 
patterns, as stimulants still form the main medication treatment for ADHD.  Although 
children with ADHD may continue with medication over a period of 2 to 6 years,[8] 
most studies report that this time is marked by intermittent periods of medication 
use.[70]  For instance, 40% reported discontinuing medication at least once during a 
3 year study period.[71]  Similarly, defining the end of a treatment course as a period 
of more than 4 months between prescriptions, 33% of children prescribed stimulants 
had more than one treatment course, indicating a pattern of intermittent medication 
use.  
Definitions of medication persistence should capture information about the 
duration of consistent and timely medication taking behavior.  However, as illustrated 
in Table 2.1, there are methodologic complexities in the study of medication 
persistence in ADHD populations.  Most studies allow for a ‘grace period’, a period 
following the end of the prescription’s supply after which, if a patient does not have 
another record of prescription/refill, the patient is considered to have ended 
treatment.  The length of time children continue with ADHD medication (persistence) 
varies somewhat with how the end of treatment is defined, however the majority of 
children who initiate ADHD medication end treatment after a short period of time.  
For example, almost 20% of a sample of newly treated children with ADHD 
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discontinued treatment after the first stimulant prescription[14] and greater than 50% 
of Medicaid patients discontinued treatment within 3 months (using a 30 day grace 
period).[9]  The mean stimulant treatment length among a group of children with 
ADHD was approximately 6 months (using a grace period equal to 150% of the 
number of days supplied by the previous prescription.[9])  Similar results were found 
among study populations that did not require an ADHD diagnosis in addition to a 
prescription for medication[14-16] as well as studies among non-North American 
populations.[72,73]  In summary, despite the range of definitions for various aspects 
of ADHD medication adherence, the overall profile of ADHD medication use is of 
short periods of treatment, and inconsistent and/or intermittent medication use.  
Also, these studies are mostly conducted using prescription or dispensing data, so 
that estimates of true adherence to medication treatment may be even lower as 
pharmacy and claims records do not indicate whether medication is actually 
consumed. 
Factors associated with ADHD medication adherence and persistence 
measures 
In efforts to identify subgroups of children who are more likely to discontinue 
ADHD medication treatment, some research has focused on the association 
between various child, parent, family, treatment and clinician factors and poor 
adherence (including medication persistence measures such as short treatment 
duration and poor continuity of treatment).  Younger children have better adherence 
to psychotropic medication than older children, in part because parents have a 
greater role in influencing medication use for younger children and adolescents may 
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be responsible for their own medication administration.[73]  Gender has not been 
consistently associated with better adherence,[14,15] nor has socioeconomic 
status.[74,75]  More severe disease and the presence of comorbidities, in particular 
oppositional defiance disorder have been found to have be negatively associated 
with medication adherence.[71,72]  Certain parental factors also affect adherence.  
Parental beliefs about pharmacological treatment, specifically when ADHD is viewed 
as a biological condition (vs. a psychological or environmentally determined 
condition) are associated with a greater likelihood of medication initiation.[10]  Level 
of parental knowledge about ADHD influences medication use, though this 
association does not extend to stimulant use over 1 year.[76]  Parental belief that the 
medication is safe and effective in reducing ADHD symptoms is positively 
associated with medication adherence.[77]  
Treatment factors, such as type and dose of medication and side effects, have 
some influence on medication adherence. Stimulants more than non-stimulants 
(such as atomoxetine) have been found to be associated with better adherence.[78]  
In particular, once-daily long-acting formulations have been consistently associated 
with improved medication adherence in comparison to the standard formulation, 
which requires several doses to maintain symptom control throughout the 
day.[16,78-80] 
Though understudied, factors related to the clinician who prescribes the therapy 
may affect medication adherence. The limited available suggests that prescriptions 
by primary care or general practitioners may be associated with shorter treatment 
lengths as compared with specialist care such as child psychiatrists,[14] perhaps 
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related to the type of care that is provided in each setting or the characteristics of 
children who are referred to specialist care.[81,82] 
More knowledge about the factors that are associated with treatment 
persistence is needed.  However the reasons for discontinuation of medication are 
not always available for study in large population-based administrative data studies. 
Information from smaller clinic-based samples may reveal potential appropriate 
reasons for medication discontinuation, such as prescribed periods where 
medication is discontinued to assess baseline symptoms, lack of response, the 
presence of side effects[60] or over the longer term, resolution of symptoms over 
childhood.[83]  However, these smaller clinic-based samples are limited by their lack 
of generalizability and small sample size.  Children who discontinue ADHD 
medication for reasons that are not clinically indicated (e.g. for reasons relating to 
medication cost, parental beliefs or child or family characteristics that hinder 
medication use) represent a group of children who cannot fully benefit from 
treatment.  Predictors of persistence are important because clinicians can then begin 
to identify children who might be more at risk of discontinuation and target 
interventions accordingly. 
In the clinical setting, if children with ADHD do not take medication as 
prescribed, clinicians cannot accurately assess short-term treatment efficacy and 
need for alterations in medication dose or type.  Given the chronic nature of ADHD 
through childhood and adolescence,[83] long-term treatment efficacy of ADHD 
medication may be complicated by poor medication adherence.[10]  In particular, the 
short periods of treatment associated with poor persistence may render some 
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children at risk of undertreatment, which may increase some of the ADHD-
associated long-term outcomes such as academic difficulties and substance 
abuse.[4,5] 
Rationale for Aim 1: 
The patterns of ADHD medication use, including measures of medication 
adherence and persistence have not been examined among children with ADHD in 
the UK, though there are differences in the clinical practices and health care system 
that may impact ADHD medication use.  Most of the research about ADHD 
medication adherence and persistence has been conducted in North American 
populations, however difference in the clinical practices and health care system may 
impact ADHD medication use. 
Major differences between US and UK practices regarding ADHD diagnosis and 
treatment include: 
1) Though a relatively recent increase in the diagnosis and treatment of ADHD in 
the UK parallels the increase that occurred in the US in the 1990’s,[84] under-
diagnosis of ADHD may be of more concern than over-diagnosis in the UK.[85]  The 
absolute rates of diagnosis are lower than US estimates[86] and are thought to 
reflect the diagnosis of more severe cases.[87]  Medication for the treatment of 
ADHD appears to be used cautiously in the UK.[82]  In fact, according to the 
National Institute for Clinical Excellence (NICE) guidelines from 2000, about 1% of 
the child population in the UK have hyperkinetic disorder (considered a severe form 
of ADHD) and it is estimated that 48, 000 of the 73, 000 children with ADHD in the 
UK are not receiving stimulant treatment. 
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2) UK guidelines have recommended that only specialist health care services 
should carry out diagnostic assessment and initiate medication for ADHD.[69,87]  
There is some evidence that this guideline is being followed in certain jurisdictions.  
For example, the majority of children who had a methylphenidate prescription issued 
by GPs were monitored by specialized services.[88]  
These two differences (that ADHD may be under-diagnosed, i.e. that only the 
most severe children are diagnosed, and that children are likely to have seen a 
specialist for initial diagnosis) motivate the question about whether ADHD 
medication persistence in the UK is markedly different to what has been described 
primarily in North American populations.  The description of treatment patterns for 
children diagnosed with ADHD in the UK is required to indicate the extent of poor 
treatment persistence and alert clinicians to a group of children who may not be fully 
benefiting from treatment.  Therefore, the first aim of this dissertation was to 
describe the initial pharmacological treatment patterns among UK children with 
ADHD and evaluate independent predictors of persistence with initial ADHD 
treatment. 
 
C. MEDICATION AND INJURY RISK AMONG CHILDREN WITH ADHD  
Evidence for an association between ADHD medication and injury risk among 
children with ADHD  
Although a recommended target outcome of ADHD therapy is to increase safety 
for these patients,[61] it is unclear if medication is associated with a decreased injury 
risk among children with ADHD.  The mechanism behind the effect of medication on 
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injury risk has been previously suggested.  The core symptoms of ADHD - 
inattention, hyperactivity and impulsivity - are all implicated as contributing factors to 
childhood injury.  Therefore, reduction in ADHD symptoms with the use of 
medication could plausible influence the associated risk for injury.  With children who 
are on prolonged, consistent treatment, medication may influence injury rates by 
facilitating improved function at home and school.  However, the available evidence 
provides an inconclusive basis for determining that medication has a positive effect 
on injury risk among children with ADHD.  Our present state of knowledge (gathered 
from clinical trial data, case study, and population-based research) is summarized 
below.  
Clinical Trial Data Post-licensing clinical trials have recorded injury outcomes for 
stimulant medication such as methylphenidate (Ritalin or Concerta) or 
amphetamines (Dexadrine, Adderall) and non-stimulant medication such as 
Atomoxetine (Strattera).[25]  The total number of injury events was usually less than 
15 in any single trial and though the proportion of children who experienced an injury 
event for groups on various types of medication were very similar (ranged from 1-
5%), medication groups as a whole tended to have fewer injury events than placebo 
groups.[89,90]  Overall, inadequate sample sizes, variations in outcome 
measurement (parental report or medical record review) and the short follow-up time 
(generally less than 12 weeks) in most clinical trials limits any inferences about the 
effect of medication use on injury risk from these studies.  
Case Studies Case studies and the clinical perspectives of psychiatrists and 
surgeons have suggested that untreated ADHD may be a risk factor in injury events 
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and that prescribed intentional medication non-use (e.g. ‘medication holidays’) may 
increase injury risk.[21,22]  For example, clinical researchers have noted that in 
many cases where children with pre-existing ADHD have suffered burn injuries, 
parents reported that stimulant medication was not taken on the day of the injury.[91]  
Further research about driving performance among adolescents with ADHD also 
supports the hypothesis that medication use can increase attention and decrease 
impulsivity, thus affecting injury risk.  For instance, methylphenidate use has been 
found to improve driving performance among adolescent boys with ADHD both when 
using driving simulators as well as during community driving.[92-94]   
Population-based research  Population-based studies have also indicated that 
medication use among children with ADHD may reduce injury outcomes.  Children 
with ADHD who were treated with medication have been found to have fewer 
emergency room visits and decreased total medical costs during periods on 
medication as compared with periods without medication, although the proportion of 
costs due to injury is not clearly delineated.[95]  This research is promising, however 
the effect of medications specifically on the injury risk of children during daily 
activities is not apparent from the above research.  
Medication adherence, the extent to which a patient is able to take a medication 
as prescribed (including obtaining the medication in the correct dose, and following 
the correct administration method and timing) is important to achieve optimum 
ADHD management.[96]  Although children with ADHD have better outcomes with 
good medication adherence,[10] this group has been found to have low adherence 
rates.[12,97]  Any effect of ADHD medication on injury risk among children with 
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ADHD will be impacted by medication adherence. 
The results of two recent population-based studies suggest that improved 
medication adherence is associated with decreased injury risk.  The first study 
compared adherence, medically-attended injuries and health care resource 
utilization between children treated with different stimulant formulations.[16]  Using a 
national (US) managed health care medical record and claims database (December 
1999 to August 2002), 1775 children ages 6-12 who initiated treatment with long-
acting (once daily) or short-acting (three times daily) MPH were followed over 1 year.  
Long-acting formulations facilitated improved adherence and were associated with a 
decreased odds of being injured over the study period, even after adjustments for 
age, gender, number of chronic medications and diagnoses, insurance type, prior 
health care costs and prior injury history (adjusted odds ratio=0.58; 95%CI: 0.35, 
0.95).  The second study by Marcus et al. selected a cohort of 11 770 children ages 
6-17 with ADHD from California Medicaid data (2000-2003).  Children were required 
to have a claim for stimulant medication (after a period of 4 months without a 
stimulant medication claim) and be continuously eligible for Medicaid during a 
treatment episode of at least 4 months.  A treatment episode started at the first 
prescription date and ended on the last day supplied by the last prescription in the 
study period.  This study focused solely on medically-attended injury outcomes as a 
function of medication adherence.  Adherence was measured using medication 
possession ratios (MPR, number of days with stimulant treatment divided by amount 
of medication prescribed).  3251 injuries were described.  After adjustment for age, 
gender, race, selected comorbidities and other psychotropic medications, medically-
   19 
attended injury rates were slightly lower for those with a high MPR (<0.7) as 
compared with those with a low MPR (<0.3) (0.227 (95%CI: 0.214,0.240) vs. 0.230 
(0.204, 0.254) injuries/person-year, adjusted hazard ratio: 0.89, p value=0.07).[26]    
Both studies contribute some evidence that overall exposure to stimulant 
medication use may be associated with fewer injuries.  However, both studies use 
administrative data that provides detailed information about medication prescription 
but provides very little information about factors relevant to medication 
use/prescription and injury. For example, information about family functioning (i.e. 
level of supervision), health-seeking behavior or ADHD severity is generally absent. 
Thus each study result may have been confounded by unmeasured differences 
between the groups.  For example, if unmeasured factors such as ADHD severity 
were associated with increased exposure to stimulant medication and an increased 
risk of injury, estimates that indicate a protective effect may be underestimated. 
Alternatively if unmeasured factors were associated with exposure to medication and 
fewer injuries (such as a high level of parental supervision), a portion of the 
protective effect would be misattributed to stimulant medication. 
Rationale for Aim 1: 
Within this above body of literature, questions arise about whether previous 
estimates about the effect of stimulant medication on injury risk may have been 
affected by unmeasured confounding factors.  The existing research has not 
considered additional aspects of the association between stimulant medication and 
injury risk, such as the comparison of injury rates for children with ADHD during 
periods on and off medication, the injury rates immediately following diagnosis, or 
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the possibility that medication may have a time-varying effect over the course of a 
treatment period. 
This study addressed the above questions using methods that decrease the 
effect of confounding by inter-individual differences by using the self-controlled case 
series design. 
 
D. SUMMARY 
Significance of the study  
This study addressed two research questions.  The results yielded detailed 
information about persistence on ADHD medication treatment among children with 
ADHD in the UK and information of the effect of stimulant medication on injury risk 
among children with ADHD.  
These findings can be useful in three ways:  
Support treatment of ADHD: Primary care settings are increasingly the main 
contact point for children with ADHD.  The awareness of the extent of poor 
adherence will allow a general practitioner (GP) to better evaluate the effectiveness 
of medication.  A GP should examine medication use patterns and be aware that 
suboptimal treatment outcomes may be related to one or more treatment 
discontinuations.[70]  ADHD symptoms have both short and long-term impacts on 
development and stimulant treatment is effective for a majority of patients.  On this 
basis, the finding that medication use is short and intermittent would suggest that 
clinicians should probe for potential causes and provide appropriate support to 
families and patients when continuing treatment. 
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Promote treatment adherence: Stimulant medication use is often discontinued 
during weekends and holidays due to concerns about potential side effects of 
stimulant use (such as sleep and growth disturbances).[98,99]  Recent treatment 
recommendations now support continuous use of medication, recognizing that 
medication also benefits the development of positive family relations and 
participation in non-school activities.[61]  As a result of this research, injury 
outcomes can be added to this list of additional benefits to encourage consistent 
medication use.  Alternatively, these findings may also support the consideration of 
injury outcomes in the decision to initiate medication and discontinue medication for 
short periods of time.  
Prevent injuries: Injury is an important preventable outcome among children with 
ADHD.  Findings supported the hypothesis that stimulant medication treatment can 
decrease injury risk, and thus, the safety of children with ADHD can be improved to 
facilitate better long-term outcomes.  Up to 15% of children experience a medically-
attended injury during each year in the UK.[36]  Children with ADHD experience a 
disproportionate number of these injuries.[17-19]  Effective treatment may be able to 
prevent injuries as well as the potential injury sequelae that can greatly impact 
development and family functioning.  The use of developmentally-appropriate 
interventions, including stimulant medication, may contribute to improved outcomes 
for children and their families while reducing burden on the health care system over 
the long term.  
  
 
 Table 2.1: Summary of selected literature regarding adherence and persistence measures with ADHD medication* 
 
 
Author, 
country, year 
N 
(age 
range) 
Design Measure* Definition Results Notes 
 Perwien et al 
United States 
(2004)9 
735 
 
(0-18 
yrs) 
Longitudinal study using 
pharmacy managed care 
data about children newly 
treated for ADHD  
Follow-up = 18 mths 
Compliance  
(days) 
 
 
Persistence  
 
MPR >0.8 
 
 
 
MPR >0.3 
Mean (SD) = 34.2 (7.6) 
 
 
Mean (SD) = 200.9 (204.5) 
 
MPR, 
medication 
possession 
ratio= days 
supplied/ 
days until next 
fill 
 Marcus et al.  
United States 
(2005)79 
11 537 
 
(6-17 
yrs) 
Longitudinal study of 
California Medicaid claims for 
initial prescriptions for 
extended-release (ER) MPH 
or immediate-release (IR) 
MPH 
Follow-up = 18 mths. 
Continuity 
(days) 
First prescription to 
gap of >30 days in 
days supplied of any 
ADHD medication  
ER-MPH: 
mean (95%CI) = 157.9 
(153.7, 162.1) 
 
IR-MPH:  
mean (95%CI) = 128.1 
(12.6, 130.6) 
grace period 
i.e. lapse in 
prescription 
supply = 30 
days 
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Winterstein et 
al. 
United States  
(2008)70 
40 052 
 
(5-20 
yrs) 
Longitudinal analysis of 
Medicaid claims among 
children with ADHD 
 
Persistence at 6 
mths, 1 yr, 2 yrs 
(proportion) 
Medication use at 
time point after the 
first drug claim 
1 month grace period: 
46.4% (6 mths) 
26.9% (1 yr) 
3 month grace period: 
49.9% (1 yr) 
32.8% (2 yrs) 
grace period = 
1 mth, 3 mths 
 Christensen et 
al. 
United States 
(2010)78 
60 010 
 
(6-18 
yrs) 
Retrospective study using 
claims database among 
children with ADHD with >1 
ADHD medication claim  
Persistence 
 
 
 
 
Adherence  
Number of days out of 
366 (follow up period) 
on their initial therapy 
Number of days of the 
initial therapy 
supplied/ total number 
of days persistent  
 254.2+140.6 (stimulants) 
vs. 154.3+149.2 (non-
stimulants) 
 
 
0.57+0.32 (stimulants) vs. 
0.49+0.38 (non-stimulants)  
 
     *MPH = methylphenidate, SD = standard deviation, mths = months, yr = year 
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Author, 
country, year 
N 
(age 
range)* 
Design Measure* Definition Results Notes 
 Did not require ADHD diagnosis 
 Miller et al 
Canada 
(2004)14 
16 945 
 
(0-19 yrs) 
Retrospective analysis of 
longitudinal linked prescription 
and health information for 
children with at least >1 
prescription for MPH 
Persistence 
 
 
 
 
 
Continuity 
Length of medication 
between first and last 
prescription 
 
 
Proportion of patients 
who had multiple 
courses of treatment 
Mean = 584 days (19.2 
mths) 
 
 
 
 
Mean treatment course = 
6.8 mths 
15% of the courses ≥1 year 
33% had > 1 course 
Grace period 
= 4 mths  
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Lage & Hwang  
United States 
(2004)16 
1775 
 
(6-12 
years) 
Longitudinal study using 
managed care health care 
data base for children with at 
least 1 prescription for MPH 
Follow-up = 12 mths after 
initial prescription 
Persistence 
 
 
 
 
Discontinuation 
No discontinuation or 
gaps >14 days over 
follow-up period 
 
Gap greater than 28 
days 
12% (ER-MPH) vs. 1% (IR-
MPH) 
 
 
 
47% (ER-MPH) vs. 72% 
(IR-MPH) 
Grace period 
= 14 days 
 Sanchez 
United States 
(2005)15 
 
9549 
 
(5-18 yrs) 
Retrospective analysis of 
Medicaid claims among 
children with at least 1 ADHD 
drug claim Follow-up= 180 
days after index claim 
Persistence  
 
 
 
 
 
Adherence 
Sum of treatment 
periods/180.  
 
Proportion persistent 
on initial stimulant 
 
MPR 
Mean (SD)= 0.50+0.33 (ER-
MPH) 
 
30.2% persist until 150-180 
days 
 
76+0.37 (ER-MPH) 
Grace period 
= 15 days 
used to 
determine 
treatment 
periods 
 Conducted outside North America  
  44 
 
(15-21 
years) 
Longitudinal study of 
adolescent aged 15 and 
prescribed ADHD medication 
in 1999 using primary care 
health data  
Treatment 
duration 
Time from first 
prescription to end 
date of the supply of 
the last prescription 
Median (95%CI)= 1.80 
(1.04-2.56) years 
Grace 
period= 6 
months 
                 *MPH = methylphenidate, SD = standard deviation, mths = months, yr = year  
 
  
 
 
III. STATEMENT OF SPECIFIC AIMS 
This research addressed the following questions: 
1) What are the patterns and predictors of ADHD medication use among 
children with ADHD? 
2) Does the use of stimulant medication change the risk of injury among children 
with ADHD?  
To answer these questions, the following specific aims were addressed in this 
research: 
 
Specific Aim 1  
To describe the initial pharmacological treatment patterns among UK children 
with ADHD and evaluate independent predictors of persistence with initial ADHD 
medication treatment. 
Hypothesis - Specific Aim 1  
The extent of poor treatment persistence (short initial treatment length (< 6 
months), presence of multiple (>1) periods of medication non-use) will be similar or 
less frequent in comparison to previous North American estimates.  Younger age at 
ADHD diagnosis and long-acting medication formulation (vs. standard 
methylphenidate (MPH)) will be associated with persistence on initial ADHD 
medication treatment. 
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Rationale for Specific Aim 1  
North American research has demonstrated that persistence with ADHD 
medication is poor in comparison to clinical guidelines.[12]  Different diagnostic and 
treatment practices in the UK may affect persistence estimates of which factors are 
associated with persistence, however no descriptive research exists.  Parental 
involvement in the decision-making and the administration of ADHD medication may 
be higher among children who are younger.  Once-daily long-acting MPH may be 
more convenient than standard formulations of MPH that require several doses each 
day.  These factors may positively influence persistence with ADHD medication. 
Poor persistence may reflect a population of children who are not receiving optimum 
treatment for ADHD. 
  
Specific Aim 2 
Assess the association between stimulant medication and risk for injury among 
children with ADHD who have been treated by comparing injury rates during periods 
of stimulant medication use to rates during untreated periods (including untreated 
time prior and after medication initiation). 
Hypothesis - Specific Aim 2  
Injury risk among children with ADHD who have been treated with medication is 
lower during treated periods as compared with untreated periods.  Stimulant 
medication use will have a similar protective effect on injury rates during the initial 
month of treatment as during the remainder of the treatment period. 
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Rationale for Specific Aim 2 
Prior studies that suggest that stimulant medication use may be protective for 
injury among children with ADHD compared groups of children,[16,26] therefore 
previous estimates may have been confounded by unmeasured between-group 
differences.  Additionally, these studies did not utilize detailed information about the 
treatment periods of stimulant medication to describe injury risk.  Study designs that 
utilize within-child comparisons to describe injury risk in treated and untreated 
periods may aid in further understanding the association between stimulant 
medication and injury risk. 
  
 
 
IV. METHODS 
This research consisted of two components 1) an analysis of prescription 
patterns and the associations between various child, clinical and treatment factors 
with ADHD medication persistence (Specific Aim 1), and 2) an analysis of the 
association between stimulant prescription and risk for injury among children with 
ADHD (Specific Aim 2).  The methods that are common to both components will be 
described, followed by the methods specific to each component.  Information from 
the(The Health Improvement Network (THIN) database was used for all analyses.  
The University of North Carolina Public Heath and Nursing Institutional Ethics Review 
Board approved the study protocol. 
 
A. DATA SOURCE  
This research used data from THIN, a longitudinal dataset with information about 
6.9 million patients (June 2008) accumulated since 1988 from general practices in 
the United Kingdom.[100]  The THIN dataset includes anonymous demographic, 
medical and prescription information at the patient level.  General practices within 
the THIN scheme use a computer software program (Vision) to maintain an 
electronic patient medical record.  This is a working clinical record that a GP uses to 
record each consultation.  This software enables the transfer of anonymized patient 
information monthly to CSD Medical Reseach (a UK research organization). CSD 
Medical Research processes this data, ensures practice and patient anonymity and 
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maintains an updated master dataset. CSD Medical Research also acts as the THIN 
data steward, facilitating the use of this primary care data for health research 
purposes by creating study subsets, training researchers on the use of the data and 
assisting with additional data collection if required.  The data are organized in files 
by individual practice and provide a longitudinal record for each patient.  The 2008 
THIN data includes information about 2.3 million patients who were actively 
registered with 386 general practices.  THIN data (June 2008) is obtained from 
approximately 4% of the UK population and has an age, gender and geographic 
distribution that similar to the population of the UK (Figure 4.1).  Almost all UK 
residents are registered with a General Practitioner (GP) practice.  The UK National 
Health Service provides universal coverage and therefore it is unlikely that any 
group within the population has been systematically excluded from accessing health 
care.  Research using THIN data has the advantage of being highly generalizable to 
the UK population. 
THIN data contains information about date of patient’s registration with the 
practice, date of transfer out of the practice, and date of death.  The data includes 
the dates of all patient visits to their GP, as well as medical assessment and 
diagnosis information and prescription details.  Since the GP functions as a 
gatekeeper of patient information and health care services within the UK health care 
system (National Health Service, NHS), information about referrals to specialists and 
hospitalizations (e.g. treatment outcomes and discharge reports) are recorded in the 
patient record based on correspondence from other facilities and professionals.   
Patient demographic information, including age, sex, and socioeconomic status 
   29 
are available.  Unique patients are tracked in the database by practice and individual 
anonymized identifiers. Household identifiers are also available so that patients 
residing at the same address can be selected (if they attend the same GP practice).   
 Extensive outcome information is available within THIN.  Signs and symptoms, 
diagnoses, procedures and investigations are coded using the Read clinical 
classification system which can, in turn, be loosely mapped by researchers onto the 
International Classification of Diseases Ninth Revision (ICD-9) and the Classification 
of Surgical Operations and Procedures Fourth Revision.  All medical diagnoses and 
any additional free text comments by the physician are recorded.  For example, 
symptoms, diagnoses and referrals will be recorded directly in the patient’s record 
during each general practice visit.  Health care received at other locations (e.g. 
emergency departments, specialists appointments and inpatient hospitalization) will 
be transcribed from discharge summaries or letters sent by specialists.  Information 
on prescriptions from the GP is recorded, including prescription dates, details on 
formulation, strength, prescription quantity and dosing instructions.  The majority of 
prescriptions are directly included in the database, since the GP generates the 
patient copy of the prescription by computerized entry.  Actual prescription 
dispensation is not recorded. In the UK context however, stimulant medication 
prescriptions are generally given for 30 days and patients need to contact the GP for 
refills and further prescriptions. This ongoing GP contact is reflected in THIN and 
allows researchers a better understanding of which prescriptions are more likely to 
have been filled. Also, indication for treatment and events leading to discontinuation 
of a drug treatment are not directly associated with the prescription records. 
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Prescriptions provided by hospital doctors or other specialists will not appear 
directly in THIN unless the treatment is to be continued by the GP.  As hospital 
prescribing budgets are limited, many prescriptions issued outside the GP office are 
sufficient only for a few days, often this can be the first 7 days, after which the 
patient is required to return to the GP for further prescriptions.  Details of ongoing 
outpatient specialist care (including any prescriptions) that are relevant for clinical 
care will be summarized by the GP in the patient record.   
The quality of the data is monitored through ongoing training on the use of the 
software and feedback reports to the practices and comparison of THIN 
consultation, prescription and death records to UK national statistics.  The database 
has been used in numerous pharmacoepidemiological studies.[101-103]  Validation 
studies have reproduced commonly found epidemiological associations[104] and 
further validation is underway. 
This dataset is uniquely suited for this research question because it is a large, 
longitudinal population-based dataset with information about community and hospital 
contacts over time, ADHD diagnoses, medically attended injury and detailed 
prescription information.  
 
B. METHODS COMMON TO BOTH SPECIFIC AIMS 
i) THIN data structure 
THIN data is provided in the form of 6 main datasets with individual level 
information.  A unique identifier (created by the combination of the practice identifier 
and the patient identifier) can be used to link the files.  This study utilized three main 
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datasets from the THIN data, the ‘patient’ file (contains one observation per person 
about demographic and registration information), the medical’ file (contains date and 
diagnostic information about each clinical event (one observation per event)), and 
the ‘therapy’ file (contains details about prescriptions and the date issued (one line 
per prescription)).  Tables 4.1, 4.2 and 4.3 list the variables available in each of 
these three datasets. 
THIN data also includes 3 other datasets, an ‘additional health information’ 
(additional lifestyle data, diagnostic and laboratory test results, death details, 
physical measurements and immunization information), ‘dosage’ (including dosage 
values and free text comments about prescription dosage) as well as a ‘postcode 
variable indicators’ dataset (postal code level information about urbanicity, ethnicity, 
environmental measures and deprivation).  Information about these additional tables 
as well as the numerous tables containing code lists and variable values will be 
discussed as relevant and can be found in the THIN Guide for Researchers©.[100] 
ii) Data acquisition 
Rather than transfer the entire THIN database, a request was made for a 
subgroup of patients from which the study groups could be derived.  
The comprehensive list of ADHD-related conditions and symptoms were 
generated using a key word search of the Read medical code dictionary and the use 
of the hierarchical structure of the Read codes to capture all ADHD-related diagnosis 
codes.  The initial request codes are outlined in Appendix A Table A.1. Similarly, a 
list of all formulations and doses of UK-recommended ADHD medications was 
compiled from the THIN drug dictionary (Appendix A Table A.2). The records of all 
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research acceptable patients who had an ADHD-related diagnosis code or a 
prescription for ADHD medication at any time were requested.  
Data from Jan 1 1993 to June 31, 2008 for 17 357 individuals were made 
available for this study.  The ‘patient’ file (number of observations=17 357), the 
associated ‘medical’ records (number of observations = 1 350 399) and therapy 
records (number of observations= 1 558 405) were received as SAS files.  The 
corresponding ‘additional health information’, ‘dosage’ and ‘postcode variable 
indicators’ files were also received. 
iii) Defining the overall study group: children with ADHD 
The following three variables were needed to select the overall study group of 
children with ADHD from the 17 357 patients received in the subset of THIN data.  
Following the definition of these three variables, the steps taken to define the overall 
study group are outlined.  These steps are summarized in Figure 4.2. 
The three additional variables needed to define the overall cohort were age at 
initial diagnosis, the start and end dates of practice data and initial ADHD diagnosis 
date. 
1) Age at initial diagnosis: Age at initial ADHD diagnosis date was determined by 
using the year of birth variable in the ‘patient’ file.  Month of birth is recorded as the 
first day of the birth month for children who were under the age of 15 at the last data 
collection date (June 30 2008).  The ‘yob’ variable for children older than 15 years 
indicates only the year of birth. 
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2) Limitations on the study group were made based on practice level 
information: The THIN ‘practice’ file provided information for each of 386 practices 
about the:  
- date of computerization (the date the practice started issuing prescriptions from the 
computer consistently) 
- the Vision date  (the date the practice start using Vision software to record 
consultations) 
- the Acceptable Mortality Reporting date (the date the practice was deemed to be 
accurately reporting all-cause mortality at a rate acceptably similar to the local 
expected rate) 
- the date of the last data collection 
When practices switch computer systems (i.e. switch to Vision software), 
records of dead patients may be deleted, resulting in periods of time (prior to the 
Vision date) when death is not recorded.  Therefore, only information recorded after 
the Vision date was used in the selection of the study group.  Two practices had not 
achieved the ‘acceptable mortality reporting’ status at the date of the last data 
collection date. 19 patients from these two practices were excluded. 
3) ADHD diagnosis: The definition of ADHD for this study aimed to include 
children with a diagnosis of Attention Deficit Disorder with and without hyperactivity 
(ADHD), and hyperkinetic disorder (HD).  The term ‘attention deficit hyperactivity 
disorder’ is used in the current American diagnostic classification system (DSM-IV). 
Hyperkinetic Disorder (HD) is the equivalent to ADHD under the ICD-10 
classification system.  ADHD as defined in the DSM-IV is a broader category than 
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Hyperkinetic Disorder, with ADHD more often used in North America and HD 
traditionally used in the UK and Europe[27]  ADHD is thought to include children with 
HD; both require an early onset of symptoms (before age 7) and require the 
presence of symptoms in more than one setting.  The main difference between the 
diagnostic systems is in the range and number of symptoms required for diagnosis.  
ICD-10 diagnoses require symptoms from each of three symptom groups 
(overactivity/hyperactivity, inattention and impulsiveness) whereas ADHD can be 
diagnosed by DSM-IV criteria with symptoms from only the hyperactive/impulsive 
symptoms or the inattentive symptoms (or both).[105]    
 In the absence of validation studies regarding ADHD diagnosis in THIN data, 
the following process was used to generate a list of Read codes that would define an 
ADHD diagnosis for the purposes of this study. 
The initial diagnosis date was determined for patients who had at least one 
ADHD-related Read code in their records.  The first record of an ADHD-related code 
that occurred at least 1 year after registration, was preceded by at least 1 year 
without a prescription for ADHD medication, and occurred when the child was less 
than 19 years old and during the study period was considered the initial diagnosis 
date.  The most frequent ADHD-related code as an initial ADHD diagnosis event is 
presented in Appendix A Table A.1.  The trends in the three most frequent ADHD 
related Read codes over the study period was described (Figure 4.3). 
The frequency as an initial diagnosis and the description of each ADHD-related 
were reviewed to select the codes used to define the ADHD cohort. 
The Read codes used to define ADHD in this study are shown in Appendix B 
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Table B.1 and included any code that referred specifically to attention deficit disorder 
(ADD), attention deficit hyperactivity disorder (ADHD) or hyperkinetic disorder, plus 
the 2 most common ADHD-related Read codes found on the initial diagnosis date 
among this group of children. 
The overall study group was defined as all individuals aged 1 to 18 with an 
incident diagnosis of ADHD that occurred between January 1, 1994 and June 30, 
2008.  Individuals were required to be registered a minimum of 1 year prior to the 
initial ADHD diagnosis. 
 
The selection of the overall study group was achieved in the following steps: 
 
1. Individuals from practices that had not achieved 
an AMR status by June 30 2008 were excluded 
  
n=19 
2. Individuals who were not age 1-18 at any time 
between Jan 1 1994 and June 30 2008 were 
excluded 
  
 
n=3285 
 
These steps resulted in 14 053 remaining patients who had either an ADHD 
diagnosis (Appendix B Table B.1) and/or a prescription for ADHD medication 
(Appendix A Table A.2) 
 
3. Children who had at least one of the following 
characteristics were excluded  
 
  
n=9819 
 3a. First ADHD diagnosis record at age >19. 
Rationale: Study group definition only includes children age 
<19 years at ADHD diagnosis.  
 
 
 3b. ADHD diagnosis prior to the registration date. 
Rationale: The registration date is considered the first 
contact between the GP and the patient, therefore any 
information with dates prior to the registration date was 
considered to be a reference to the patient’s medical history. 
 
 
 3c. Less than 1 year between registration and the first ADHD 
diagnosis. 
Rationale: When a patient registers with a new practice, past 
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diagnosis and events may be recorded using the date of 
data entry. Disease incidence rates tend to be higher in the 
first year after registration with a GP as the diagnoses that 
are part of the medical history are added to the patient 
record,[106] therefore this criteria was used to insure that 
ADHD diagnosis was not reflective of a previous diagnosis 
recorded at or within a year of the time of registration.  
 
 3d. Record of ADHD medication prescription without an 
ADHD diagnosis. 
Rationale: The study group was defined by an ADHD 
diagnosis, therefore children who were prescribed 
medication without a diagnosis were excluded. 
 
 
 3e. Record of ADHD medication in the one year prior to the 
ADHD diagnosis date. 
Rationale: To ensure that children with ADHD who were 
treated with ADHD medication were new users of 
medication. 
 
 
 
The remaining 4234 patients were considered the overall study group of children 
with ADHD. 
 
 
 
For each Specific Aim, additional restrictions were made to establish the aim-
specific study group.  These restrictions are detailed in the methods section relevant 
to each Specific Aim and summarized in Figure 4.2. 
ii) Definition of variables common to both Specific Aims 
Age group: Children less than age 6 were grouped separately as the identification 
and treatment of children diagnosed with ADHD prior to the age of 6 is less 
prevalent, especially in primary care.  Additionally, stimulant medication such as 
methylphenidate is not approved in the UK for use under the age of 6, and treatment 
guidelines state that pharmacological treatment of those with ADHD under 6 should 
be initiated by a specialist.[69]  Children ages 15-18 years were also grouped 
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separately as the diagnosis and medication use patterns change as adolescents 
with ADHD transition to adult health care services.[107] 
Medication type: Methylphenidate (MPH), dexamphetamine and atomoxetine were 
the only types of medications approved for ADHD treatment in the UK during the 
study period[69]  MPH and dexamphetamine are stimulant medication; atomoxetine 
is a non-stimulant.  Records of all formulations and strengths of all medication types 
were included in the definition of ADHD medication.  Appendix A Table A.2 includes 
information about which stimulant medications were considered long-acting 
medication (i.e. medication that is effective for 8 to 12 hours) and which were 
considered standard formulation stimulants.   
iii) Other methods common to both Specific Aims 
Analyses were conducted using SAS software (SAS Institute Inc, Cary, NC, 
USA).  
 
C. METHODS - SPECIFIC AIM 1 
i) Study group definition 
For Specific Aim 1, additional criteria were applied to define the study group: 
1) Children with less than 2 years follow-up after initial diagnosis 
were excluded (n=1262).  Rationale: This restriction was made 
to allow estimation of the proportion of children with ADHD who 
are treated with ADHD medication within two years. 
2) Children with less than 1 year follow-up after initial medication 
prescription were excluded (n=62).  This restriction was made to 
   38 
avoid using these children in describing the characteristics of 
prescription patterns in the first year after medication initiation. 
Therefore, the study group for Specific Aim 1 included 2910 children (Figure 4.2). 
ii) Definition of variables 
Prescription records that were included for study were limited to those after the 
diagnosis of ADHD, prior to the end of follow-up (earliest of death date, transfer 
date, date of 19th birthday, last data collection date).  The following variables were 
constructed from these data. 
ADHD medication: ADHD medication was defined as the three types of 
medications approved for the treatment of ADHD in the UK during the study period: 
methylphenidate (MPH), dexamphetamine and atomoxetine.  Records of all 
formulations and strengths were included in this definition. 
Treated with medication: Children were considered treated if 1 or more 
prescriptions for ADHD medication were recorded within the first 2 years after initial 
diagnosis.  
Initial medication type: Children were classified according to the first type of 
medication initially prescribed. 
Time between diagnosis and initiation medication treatment: The number of 
days between diagnosis and initial medication treatment was categorized into 8 
categories (on diagnosis day, 1-30 days, 31-60 day, 61-90 days, 91-120 days, 121-
180 days, 18-365 days, 1-2 years). 
 
 
   39 
Medication persistence measures 
Measures of persistence should capture information about the duration of 
consistent and timely medication taking behavior.[13]  Two measures of persistence 
with ADHD medication were described; initial treatment course duration, a binary 
variable indicating persistence at 6 months and for children with >1 treatment 
course, the length of the gaps between treatment courses. 
Initial treatment course length:  Initial treatment course length was defined as the 
amount of time between the date of the initial medication prescription and the end of 
the treatment period of the last ADHD medication prescription.  
Persistence:  Children were classified as persistent (initial treatment course length 
> 6 months) or non-persistent (initial treatment course length < 6 months). A six 
month cut point was chosen to allow sufficient time to use medication after 
establishing an effective dose. 
Gaps between treatment courses:  A gap between treatment courses was defined 
as the number of days from the last day supplied in a treatment course to the date of 
the next prescription.  Among children with more than one treatment course, the 
length of the gaps between all treatment courses was examined within the entire 
follow-up period. 
Grace period used in the determination of treatment course length:  The length 
of the grace period used in the determination of medication persistence may be 
based on the medication half-life, clinical efficacy and/or as a set multiple of the 
number of days supplied by the previous prescription.[13]  A 30-day grace period 
was chosen so that children who take medication only during the school week would 
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not be misclassified as having discontinued treatment.  Additionally, a 30 day grace 
period has previously been used to examine ADHD persistence[78,79,108] and 
medication adherence using administrative data.[109]   
Days supplied by each prescription:  For most (55%) of the prescriptions with 
non-missing daily dose and prescription quantity values, the calculated number of 
days supplied by each prescription was 30 days (82.0% were between 28 and 32 
days).  Therefore missing ‘days supplied’ values were set to 30 days, which also is 
the recommended prescription length for controlled drugs (such as ADHD stimulant 
medication) in the UK[110]   
Socioeconomic status: Socioeconomic status (SES) may be related to medication 
initiation, adherence and treatment persistence [11,111] and therefore will be used 
as a covariate in the analyses related to Specific Aim 1.  Socioeconomic status in 
THIN data is measured using the Townsend deprivation index.  The index ranks 
levels of deprivation on a scale of 1 to 5 by quintile from least to most deprived 
based on the postal code of the patient’s home address.  Four variables derived 
from 2001 UK census data are used to calculate the Townsend index:  
- the percentage of households without access to a car 
- the percentage of households not in owner occupied accommodation 
- the percentage of households in overcrowded accommodation 
- the percentage of the economically active population age 16-74 who 
are unemployed  
The Townsend index is assigned to postal codes and each area corresponds to 
approximately 150 households.  Changes in Townsend scores are updated by 
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including additional records when differences are found between subsequent data 
collections.  Thus, THIN records for each child could include up to 5 Townsend index 
values and the associated update date. 
For children who had more than one value the Townsend value that was closest 
to the initial ADHD diagnosis date, but not after, was chosen to represent baseline 
SES status in Aim 1 analyses.  Of the overall cohort of 2901 children with ADHD, 
2708 (93.3%) had at least 1 Townsend value.  
Psychiatric comorbidity: Psychiatric comorbidities, such as conduct disorders, 
anxiety disorders and depression are common in among children with ADHD and 
have been associated with treatment adherence.[71]  
The definition of a psychiatric comorbidity was the presence of at least 1 record 
with a relevant psychiatric cormorbidity Read code prior to the initial ADHD 
diagnosis day.  To identify children with psychiatric comorbidities the following 4 
steps were taken for each of three comorbidity types (conduct disorders, anxiety 
disorders and depressive disorders): 
1. A list of relevant keywords was derived by review of the Read code 
dictionary and relevant literature. 
2. A list of Read codes that included at least 1 relevant keyword was 
generated. 
3. Manual review of the resulting list informed the generation of a list of 
keywords that was used to exclude irrelevant codes. 
4. The resulting Read code list was used to define the psychiatric 
comorbidity. 
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Appendix C lists the keywords for inclusion, keywords for exclusion and the 
resulting Read Code list that define each psychiatric comorbidity.  
Specialist Contact:  Children are generally seen by their GP, who may identify a 
potential health problem and then refer to a specialist (pediatrician or psychiatrist) for 
confirmation of a diagnosis and initiation of interventions, including medication or 
behavioral parent training.  A Read code for ADHD may appear in a patients’ 
records with or without a subsequent specialist referral and documentation of the 
specialist diagnosis.  Guidelines suggest that children be seen by a specialist during 
which time the response to the medication treatment is monitored.[112]  After a 
diagnosis has been confirmed, the patient’s clinical condition is stable and/or the 
medication regimen has been established, children are to return to the care of a 
general practitioner for ongoing care and monitoring.  Specialists may have children 
return for monitoring visits at 6 to 12 month intervals.[60]   
ADHD management recommendations state that a specialist review letter should 
be sent to each child’s GP after initial assessment and following each further 
appointment and thus should be recorded in THIN data.[113]   
Specialist related records were identified as records in the  ‘medical’ file with at 
least one of the following: 
a) a ‘medflag’ variable value of ‘S’ which indicates an additional referral or 
request event  
b) Read code that indicates a referral procedure.  THIN researchers have 
previously generated a list of 598 Read codes that may indicate a 
referral event.  Codes that occurred more than 5 times among records 
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from the same day as the initial ADHD diagnosis were reviewed.  Read 
codes were selected if relevant to a diagnosis of ADHD (letter from 
hospital, or referral to child psychiatric).  The selected Read codes are 
presented in Appendix D Table D.1. 
c) A ‘source’ variable value indicative of a referral event (Appendix D 
Table D.2). 
d) A ‘locate’ variable value that indicates that the record represents a 
‘letter from outpatients’ or ‘referral letter’ 
The presence of any one of these features for a record that occurred on the 
same day as the initial ADHD diagnosis was considered indicative of a ‘specialist 
contact on the initial diagnosis date’.  
iii) Analysis 
Proportions and cross tabulations were used to describe i) gender, age at 
diagnosis, and the proportion treated among all children diagnosed with ADHD, and 
ii) time from diagnosis to treatment, initial drug type and treatment gap lengths 
among treated children.  Kaplan-Meier survival analyses were used to describe the 
length of the initial treatment course. 
The proportion of children who persisted with initial treatment beyond 6 months 
was the outcome of interest.  Rather than build a predictive model that would require 
validation within a subset of the cohort, selected covariates of interest were entered 
in a multivariate model to estimate the independence of associations with the 
outcome.  The outcome distribution was compared by child covariates (e.g. gender, 
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age at diagnosis) and clinical covariates (e.g. involvement of specialist) using log-
binomial regression to estimate risk ratios (RR) and 95% confidence intervals (CI).  
The regression model formula used to examine the association between these 
factors and persistence at 6 months is: 
 
Log (persistence) = α + β1 gender + β2-4 age group + β5 diagnosis year + β6-9 
SES+ β10 comorbidities + β11 specialist + β12-14 med type + β15-21 time to treat 
 
where log(persistence) = log probability of persistence 
α = baseline log prevalence of persistence 
gender = binary variable (0=boys, 1=girls) 
age group = 4-category variable (three indicator variables) for age group at 
diagnosis (1-5 years, 6-9 years (reference group), 10-14 years, 15-18 years) 
diagnosis year = binary variable for year of diagnosis (0=1993-2001, 1=2002-2006) 
SES = 5-category variable (four indicator variables) for socioeconomic status 
(1=least deprived (reference group), 5=most deprived) 
comorbidities = binary variable for anxiety, conduct or depressive disorder prior to 
ADHD diagnosis (0=no, 1=yes) 
specialist = binary variable for specialist contact on diagnosis day (0=no, 1=yes) 
med type = 4-category variable (three indicator variables) for initial medication type 
(MPH (reference group), dexamphetamine, atomoxetine, long-acting MPH) 
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time to treat = 8 category variable (7 indicator variables) for time between diagnosis 
and medication initiation (on diagnosis day (reference group), 1-30 days, 31-60 
days, 61-90 days, 91-120 days, 121-180 days, 180-365 days, 1-2 years) 
 
D. METHODS – SPECIFIC AIM 2 
i) The self-controlled case series design  
The self-controlled case series design is able to estimate an association 
between a time-varying exposure and an outcome event by making within-person 
comparisons in a population of individuals who have experienced the outcome of 
interest.  The observation period for each person is the time during which, if an event 
arose, it would be sampled.  The case series likelihood is based on the probability 
that an event occurred when it did relative to the exposure periods, given that the 
event occurred during the observation period.  The study group therefore consists of 
only cases, and individuals that have never been exposed do not contribute to the 
estimate.  The observation time for each individual is divided into exposed and 
unexposed periods that may vary in duration. 
Similar to the traditional Poisson cohort method on which the self-controlled 
case study is based, the self-controlled case series produces relative incidence rate 
ratios, i.e. the ratio of the rate of events in exposure periods to the rate of events in 
the periods without the exposure.  The self-controlled case series design is closely 
related to the case-crossover design.[114]  
The main advantage of the self-controlled case series method is that the use of 
within-person comparisons allows the control of fixed characteristics such as 
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genetics, sex, socioeconomic status and underlying health status.  Also, only cases 
are needed.  The method assumes that these intra-individual factors and their 
effects on baseline risk remain stable over the study period.  The method is useful in 
situation where inter-person confounder information may be difficult to obtain and 
measure accurately.  The case series also has the benefit of using only cases, which 
is relevant in situations where the cost and effort may impact sample size.  As well, 
the case series method has the benefit of permitting exploration of changes in risk 
with duration of exposure and the ability to control for factors that may vary over the 
study period (such as age). 
The limitations of this method relate to 2 main assumptions that must be met for 
the results to be valid: 1) the occurrence of the event does not affect the distribution 
of the exposure and 2) events are independent within a person.  These assumptions 
are addressed in the section iv) Application of the self-controlled case series 
method. 
ii) Study group definition 
The group definition was refined to select children from the overall study group 
who had both a record of the exposure (stimulant medication) and the outcome 
(medically-attended injury) after a diagnosis of ADHD.  The following groups were 
deleted. 
1) Children with ADHD who were not treated (i.e. did not have at least 
one prescription for ADHD stimulant medication) were excluded 
(n=2474). 
2) Children who were not injured (n=897) 
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3) Children who did not have an incident injury event at least 1 year 
following registration date were excluded  (n=75). 
4) Children with an incident injury prior to ADHD diagnosis (and after the 
first year of registration) were excluded. The study outcome definition 
required that the injury occur after the child had been diagnosed 
(n=462). 
Therefore, the study group for Specific Aim 1 included 328 children (Figure 4.2). 
iii) Definition of variables 
Prescription records that were included for study were limited to those after the 
diagnosis of ADHD, prior to the end of follow-up (earliest of death date, transfer 
date, date of 19th birthday, last data collection date).  The following variables were 
constructed from these data. 
ADHD stimulant medication: Since stimulants are the only type of medication used 
for approximately 86% of children with ADHD and non-stimulants such as 
atomoxetine are associated with a different mechanism of action and onset and 
duration of effect, only stimulant ADHD medications (e.g. methylphenidate, 
dexamphetamine) were included for study in this Specific Aim.  ADHD medication 
was defined as any stimulant medication approved for the treatment of ADHD in the 
UK during the study period: methylphenidate (MPH) or dexamphetamine. Records of 
all formulations and strengths were included in this definition. 
Treated with medication: Children were considered treated if 1 or more 
prescriptions for ADHD stimulant medication were recorded after initial diagnosis.  
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Initial medication type: Observation time was classified according to the first type 
of medication prescribed to each child (standard formulation methylphenidate, long-
acting methylphenidate, or dexamphetamine). 
Stimulant medication exposure – determination of treatment time 
The ‘days supply’ value for each prescription and the grace period used in this 
study were determined as outlined in the section entitled ‘Methods – Specific Aim 1’. 
Treatment periods: Starting from the date of diagnosis, observation time was 
categorized as treated or untreated. A treatment period started on the day a 
stimulant was prescribed and extended until the end of the ‘day supplied’ value plus 
a 30 day grace period.  Untreated periods were all observation time that was not 
classified as treated.  Each child could have multiple stimulant treated and untreated 
periods.  To assess for differences in the effect of medication according to the time 
since the start of the treatment course, observation time during the first 30 days of 
each treatment course were classified separately from observation time occurring 
after the 30th day of treatment.  Untreated time prior to medication initiation was also 
classified separately from untreated periods between courses of stimulant treatment 
and after the discontinuation of treatment (Figure 6.1). 
Season: The cut points of March 31, June 30, September 30, December 31 were 
used to divide calendar time into 4 seasons. 
Injury outcome: Records of medically attended injury are included in THIN from 
three main sources: general practice visits, emergency room visits and 
hospitalizations.  Data are available in the ‘medical’ file regarding the date and 
location of service, and procedures or referrals made as a result of the visit.  
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Injury Read codes may describe either 1) a diagnosis related to an injury and 
poisoning event or 2) the cause of an injury and poisoning event.  Ideally these two 
types of Read codes will be used together to describe the bodily injury sustained, 
and the mechanism or circumstances of each injury. 
Medically-attended injury was defined as a record with a Read code that 
indicated a diagnosis for an injury or poisoning event (Table 4.4). 
The proportion of diagnosis injury Read code records that had a record for the 
cause of injury on the same day was low (~5% of injury diagnosis codes). 
Additionally, records with a cause of injury code that was not associated with a 
diagnostic injury code were more common than expected (80% of injury cause 
codes).  Since injury outcomes have not been validated in THIN data, it was not 
possible to discern whether an injury cause code (without a diagnosis code) 
represented an injury event where the diagnosis was not recorded, or an event that 
did not result in an injury.  Therefore, only injury diagnosis codes were used to 
define a medically-attended injury. 
All subchapters of injury and poisoning diagnosis Read codes were included, 
except ‘late effects of injury/poisoning/toxic effects/external causes’ and medical 
accidents and surgical procedures causing complications’. 
Injury type was described.  Previous studies that have examined population-
based injury rates in children have divided ICD-9 injury and poisoning diagnosis 
codes into 16 main categories of injury type.[17,41]  Similarly, injury type was 
classified by subchapter of injury and poisoning diagnosis Read code (Table 4.4).  
Each child contributed a single injury event to the analysis for Specific Aim 2.   
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The ‘additional health data’ file was searched to identify additional injury events. 
No additional injury or poisoning Read codes were found, however 1 cause code 
was found relevant to a death record (see below).  
Ascertainment of death by injury 
Of the 7 children in the overall study group that were identified as having died 
during the study period (see Appendix E for methods relating to the identification of 
death), a manual review of the ‘medical’ records and ‘additional health data’ records 
was conducted to extract any additional information about cause of death.  
Two children had no additional information, 2 had some information the month 
prior to the death date that did not appear to be injury related in (e.g. ‘unexpected 
death’ or ‘influenza’) and one child had record of a fracture 10 days before the death 
date.  The time between the fracture and the date of death, as well as the presence 
of numerous other diagnoses within the last month of death, the cause of death was 
not assumed.  Two children had a record of a ‘MVA’ (motor vehicle collision) noted 
within one day of the death date.  These two children were thus classified as fatally 
injured.  Both did not have any other injuries in their records, or a diagnosis injury or 
poisoning Read code within around the death date.  The death date was entered as 
the injury date, the injury type was classified as ‘other’ and both were eligible to be 
included as injured children in the analyses for Aim 2. 
iv) Application of the self-controlled case series method 
There are three relevant methodological considerations when applying the self-
controlled case series method.  First, while the method controls for confounding by 
factors that are stable over time, time-varying risk factors for the outcome within an 
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individual may lead to within-person confounding. Therefore, two strong time-varying 
risk factors for injury, age (by age group, 1-5, 6-10, 11-14, 15-18 years) and season 
(Winter, Spring, Summer and Autumn) were controlled for in the analyses.  Second, 
events must be independent within a person, an assumption that probably does not 
hold with injuries as the occurrence of an injury may increase the risk of a 
subsequent injury.[115]  Thus this study includes only the first injury events in the 
analysis.[116]  Finally, an assumption of the self-controlled case series is that the 
treatment is not affected by the occurrence of the event.  In this study, there was 
concern that a medically-attended injury may precipitate the initial prescription of 
medication among children with ADHD.  The distribution of injuries in the 6 months 
prior to initial medication prescription was assessed and there was no indication that 
injury events precipitate initial medication.  Therefore all person-time between 
diagnosis and initial medication prescription was included in the analysis.  This 
untreated person-time before the first treatment course was excluded in a sensitivity 
analysis. 
v) Analysis 
The primary analysis assessed the impact of stimulant medication on the 
occurrence of first incident injury by comparing the rate of events during all periods of 
treatment with stimulant medication to the rate during all untreated time periods.  
Self-controlled incident rate ratios (IRR) and their 95% confidence intervals (CI) were 
estimated using conditional Poisson regression.  
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A self-controlled case series analysis uses a conditional Poisson regression 
model with a log link function examine the association between stimulant medication 
and injury event rates. 
eijkl is the amount of time spent by an individual i in age group j and season k 
and risk period l. nijkl is the number of injuries in the interval.  The incidence rate (λijkl) 
is assumed to be constant within each interval and the number of events (nijkl) 
occurring within an interval of time (eijkl) is assumed to follow a Poisson distribution 
with a rate λijkl eijkl. 
 
Ln (λijk) = φi + αj + δk + βl 
 
φI = factor for each individual 
αj  = age group of the individual during the interval (time-varying) 
δk = season of the interval (time-varying) 
βl  = factor for the risk group 
 
The log of the time spent in each interval, ln(eijkl), was included in the model as an 
offset. 
 
Stratified analyses were conducted to assess the association between stimulant 
medication and injury events by gender, age group and type of medication. 
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Sensitivity analyses  
1) Medically-attended injury:  We performed several sensitivity analyses using 
different definitions for injury events.  Types of injuries that were hypothesized 
to be more consistently medically-attended (upper limb, lower limb and skull 
fractures, head injuries) were examined separately.  Injuries were also 
stratified by the day of the week (weekend or weekday).  
2) Definition of ADHD:  The broadening of the diagnostic criteria for ADHD and 
the associated increase in stimulant treatment for ADHD in recent years may 
modify the association under study.  Children treated with stimulants before 
and after the year 2000 were therefore analyzed separately. 
3) Assumptions of the study design:  The results of self-controlled case series 
may be biased by incorrect specification of the treatment period and by the 
inclusion of events that alter the distribution of post-event treatment.  
Sensitivity analyses were undertaken to determine if the results were 
influenced by (i) varying the length of the grace period used to determine 
stimulant course length (15, 45, 60, 90 days), (ii) excluding untreated person-
time prior to medication initiation or (iii) excluding fatal injuries that obviously 
precluded post-event treatments. 
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Table 4.1: ‘Patient’ file variables 
Variable Description 
Pracid Practice identifier 
Patid Patient identifier - unique within practice. Links to other data files 
Yob Year of birth (month also included for children) 
Famnum identifier shared by patients living at same address or family members 
Sex   Sex of patient 
Regdate Patients registration date with the practice  
Regstat   Registration status 
Xferdate Date of transfer out of practice  
(if applicable) 
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Table 4.2: ‘Medical’ file variables  
Variable Description 
Pracid Practice identifier 
Patid Patient identifier  
Evntdate Event date 
Medcode Read medical code 
Medflag Flag indicating integrity of the record  
Source Variable indicating origin of record 
Episode Episode type 
NHSspec Secondary care speciality  
Locate Location of consultation  
Textid link to free text comments 
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Table 4.3: ‘Therapy’ file variables 
Variable Description 
Pracid Practice identifier 
patid Patient identifier 
prscdate Prescription date 
drugcode Multilex drug code (product and formulation specific) 
therflag Flag indicating integrity of the record  
doscode link to DOSAGE string 
prscqty Quantity prescribed can also be number of packs 
prscdays Duration of the prescription in days 
prsctype Variable denoting acute or repeat prescription 
opno Number of original packs ordered 
bnf British National Formulary 1 code  
packsize Link to free text pack size information  
dosgval The calculated daily dosage (derived by EPIC) 
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Table 4.4: Injury types by Injury and poisoning Read code subchapter 
 
Excluded  First two characters of Read code and description 
 S0 Fracture of skull 
 S1 Fracture of neck and trunk 
 S2 Fracture of upper limb 
 S3 Fracture of lower limb 
 S4 Dislocations and subluxations 
 S5 Sprains and strains 
 S6 Intracranial injuries excluding skull fracture 
 S7 Internal injury chest/abdomen/pelvis 
 S8 Open wound head/neck/trunk 
 S9 Open wound of upper limb 
 SA Open wound lower limb 
 SB Injury to blood vessels 
YES SC Late effects – injury/poisoning 
 SD Superficial injury (abrasions, blisters, stings, bites) 
 SE Contusion (bruise) and intact skin 
 SF Crushing injury 
 SG Foreign body in orifice 
 SH Burns 
 SJ Nerve/spinal cord injuries 
 SK Traumatic complications/unspecified injury 
 SL Poisoning (medicinal agent) 
 SM Nonmedical agent toxic effects 
 SN Other external effect causes (frostbite, heat, motion sickness, suffocation, 
abuse maltreatment, neglect, food allergy, anaphylactic shock) 
YES SP Surgical/medical care complications 
 SQ Open wound involving multiple body regions 
 SR Injury involving multiple body regions 
 SY [X] Injury/poisoning class terms  
 SZ Injury and poisoning 
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Figure 4.3 shows the relative patterns of use of the three most frequent codes observed among initial 
diagnosis day records, 1993-2008. ‘Child hyperkinetic syndrome’ was the most frequent codes used 
in the 1990’s, however its use diminished greatly by the year 2000. ‘[X] Attention deficit hyperactivity 
disorder’ increased in use and presently accounts for approximately 80% of codes used to refer to 
ADHD-related conditions. This pattern may be explained by the assessment and treatment guidelines 
that sanctioned the use of ADHD, which is also the more commonly used term in North America. 
Child attention deficit disorder was used up to 40% of the time in the early 2000’s however decreased 
to approximately 20% by 2008.  
  
 
 
V. RESULTS: The pharmacological treatment of children with Attention Deficit 
Hyperactivity Disorder in primary care in the United Kingdom1 
 
A.  BACKGROUND 
Attention deficit hyperactivity disorder (ADHD) affects 5% of school-age children 
worldwide.[2]  ADHD may be underdiagnosed in the United Kingdom (UK) where the 
prevalence of diagnosed ADHD is estimated at 3.6% for boys and 0.9% for 
girls.[117,118]  ADHD, characterized by core symptoms of hyperactivity, impulsivity 
and inattentiveness, is associated with academic difficulties, poor family and peer 
relationships, substance abuse and psychiatric comorbidities in childhood[3-5] and 
across the lifespan.[6] 
Pharmacotherapy (primarily stimulant medication) for short-term ADHD 
symptom reduction is effective,[7,8] however research about the long-term 
effectiveness of medication on symptoms and ADHD-associated outcomes is less 
compelling.[68]  ADHD treatment guidelines suggest a combination of behavior 
therapy, parental training[65] and medication use for as long as clinically 
effective.[69]  Adherence, defined as the extent to which a person’s behavior, 
including taking medication, corresponds with recommendations from a health care 
provider[11] has been characterized as poor among children with ADHD in the 
                                                        
1 The results in this chapter have been submitted to Archives of Disease in 
Childhood on Jan 11, 2011. Authors include the committee members listed on the 
title page. 
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United States (US).[12]  For example, one aspect of adherence, medication 
persistence, defined as the amount of time on regular and consistent drug 
therapy[13] has been estimated to be 6 months or less for stimulants.[9,79]  Given 
the chronic nature of ADHD[83], long-term ADHD treatment effectiveness may be 
complicated by poor medication adherence.[10] 
ADHD medication adherence is associated with child factors (such as age, 
gender and disease severity[14,15]) parental factors (such as parental beliefs about 
pharmacological treatment)[10] and treatment factors (such as type and dose of 
medication and side effects)[16].  In particular, once-daily long-acting formulations 
have been consistently associated with longer treatment duration and continuity in 
comparison to the standard formulation, which requires several doses throughout 
the day.[78,79] 
Despite indications that ADHD diagnosis in the UK tends to be reserved for 
more severely affected children[87], pharmacological treatment is initiated more 
cautiously than in North American populations.[82,119]  ADHD treatment patterns in 
the UK have not been described despite the need to understand the extent of poor 
treatment persistence and identify children who may not be fully benefiting from 
treatment.  Therefore, the aim of this study was to describe the initial 
pharmacological treatment patterns among UK children with ADHD and evaluate 
independent predictors of persistence with initial ADHD treatment.  
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B.  METHODS 
Study Population 
This study was conducted using data from UK-based The Health Improvement 
Network (THIN) from January 1st, 1993 to June 30th, 2008.  General practices in the 
network provide information about general practice visits, the date and details of 
prescriptions and referrals for care received in secondary care facilities. 
The study population included all individuals aged 1 to 16 with an incident 
diagnosis of ADHD that occurred between January 1, 1994 and June 30, 2006.  To 
ensure that ADHD diagnosis did not reflect a previous diagnosis recorded at the time 
of registration, individuals were registered a minimum of 1 year prior to the initial 
ADHD diagnosis.  Children were excluded if they received an ADHD medication 
prescription in the year prior to diagnosis, had less than 2 years follow-up time after 
diagnosis, or less than 1 year follow-up time after initial medication prescription. 
Patients were followed from 1 year after registration to the child’s 19th birthday, the 
last data collection date, death date or the date of transfer out of the practice, 
whichever was earliest.  
Information in THIN is coded using the Read clinical classification system.  The 
Read codes used to define ADHD (Appendix B.1) include any code that refers 
specifically to ADHD, attention deficit disorder (ADD) or hyperkinetic disorder, plus 
the 2 codes most commonly used to identify ADHD in THIN. 
ADHD Medication 
All medications approved for ADHD treatment in the UK during the study period 
were included (methylphenidate (MPH), dexamphetamine and atomoxetine).  
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Children were considered treated if 1 or more prescriptions for ADHD medication 
were recorded within the first 2 years after initial diagnosis.  Children were classified 
by first type of medication prescribed and time between diagnosis and first 
medication prescription.  
Description of the medication patterns required assessment of the treatment 
period for each prescription.  For most (82%) of the prescriptions with daily dose and 
prescription quantity values, the calculated number of days supplied by the 
prescription was between 28 and 32 days.  Therefore missing ‘days supplied’ values 
were set to 30 days, which also is the recommended prescription length for 
controlled drugs (such as ADHD stimulant medication) in the UK.[110]  The 30-day 
grace period used to define the end of a treatment course was chosen so that 
children who take medication only during the school week would not be misclassified 
as having discontinued treatment.  Additionally, a 30 day grace period has 
previously been used to examine ADHD persistence using administrative 
data.[78,79,108] 
Measures of persistence should capture information about the duration of 
consistent and timely medication taking behavior.[13]  Two measures of persistence 
with ADHD medication were described; initial treatment course duration, and for 
children with >1 treatment course, the length of the gaps between treatment 
courses. 
Initial treatment course length was defined as the amount of time between the 
initial medication prescription date and the end of the treatment period of the last 
ADHD medication prescription.  Children were classified as persistent (initial 
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treatment course length > 6 months) or non-persistent (initial treatment course 
length < 6 months).  A six month cut point was chosen to allow sufficient time to use 
medication after establishing an effective dose. 
Within the entire follow-up period of children with >1 treatment course, the 
proportion of children with periods of varying lengths between treatment courses 
was examined. 
Analysis 
Proportions and cross tabulations were used to describe 1) gender, age at 
diagnosis, and the proportion treated among all children diagnosed with ADHD, and 
2) time from diagnosis to treatment, initial drug type and the length of time between 
treatment courses among treated children.  Kaplan-Meier survival analyses were 
used to describe the length of the initial treatment course. 
The proportion of children who persisted with initial treatment beyond 6 months 
was the outcome of interest.  The association between the outcome and child 
covariates (e.g. gender, age at diagnosis) and clinical covariates (e.g. specialist 
contact) were estimated using binomial regression to generate risk ratios (RR) and 
95% confidence intervals (CI).  Analyses were conducted using SAS version 9.2 
(SAS Institute Inc, Cary, NC, USA).  The University of North Carolina Public Heath 
and Nursing Institutional Ethics Review Board approved this study. 
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C.  RESULTS  
Study Group Characteristics 
Of 2910 identified children with ADHD, 84% were male, and approximately 50% 
were diagnosed between the ages of 6.5 and 11.5 years (mean age of diagnosis: 
9.1 years (standard deviation (SD): 3.3) (Table 5.1).[120] 
The age at diagnosis increased over the study period, from a mean age at 
diagnosis of 6.6 years in 1995 to 10.0 years in 2006. The gender distribution was 
stable from 1994 to 2007.  Overall, the proportion treated with ADHD medication 
was 45% (n=1314) (Figure 5.1).  Boys were not more likely to be treated than girls 
(46% vs. 42%; p = 0.2).  Children age 1-5 (24%, n=121) and 15-18 years (36%, 
n=47) were less likely to be treated than children 6-9 (49%, n=644) and 10-14 years 
(52%, n=502). 
Of children receiving stimulant ADHD treatment, 94.1% were initially treated with 
MPH and 2% were initially treated with dexamphetamine over all years (Figure 5.1).  
The prescription of long-acting MPH formulations increased from 14% in 2002 to 
50% in 2006.  Atomoxetine was the initial prescription for 3% to 11% of children 
between 2004 to 2006, with the peak proportion in 2005. 
Approximately 20% (n=258) of the 1314 treated children were prescribed 
medication on the initial diagnosis date; 18% (n=234) were prescribed medication 
within 30 days of diagnosis.  Most treatment was initiated in the first year following 
diagnosis (87%, n=1141). 
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Medication Persistence  
The mean initial treatment course length was 10.7 months (SD=0.5). One month 
after the initial medication prescription, 70% of treated children remained on 
treatment.  At 6 months, 35% remained on treatment, falling to 27% at 9 months and 
22% at 12 months (Figure 5.2).  
Among children with more than one treatment course (n=1038), 59% (n=608) 
had a 3 month period without treatment, 31% (n=316) had a 6 month period without 
treatment and 14% (n=142) had a 12 month period without treatment (Figure 5.3).  
The mean length of the first gap (time between the end of the first treatment course 
and the start of the second treatment course) was 112 days (median= 54 days). The 
mean length of the first gap among the 324 children who discontinued medication 
treatment within 1 month was shorter than among the 714 children with longer initial 
treatment lengths (94 days vs. 154 days). 
The regression results regarding the associations between covariates and 
persistence on initial treatment for at least 6 months are shown in Table 5.2.  Initial 
drug type (long-acting MPH compared with the standard formulation; risk ratio (RR)= 
1.2; 95% CI:1.1, 1.4); and being diagnosed between 2002-2006 compared with 
being diagnosed between 1994-2001 (RR= 1.4; (95%CI:1.1, 1.7) were positively 
associated with persistence. Treatment initiation between 1 and 2 years after 
diagnosis compared with being treated on the initial diagnosis date was inversely 
associated with persistence on initial treatment (RR= 0.7; 95%CI: 0.5, 0.9). 
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D.  DISCUSSION 
These results provide three novel insights about the pharmacological treatment 
of UK children diagnosed with ADHD. First, the profile of the study group, in 
particular the age at diagnosis and the type of medication utilised has changed 
considerably between 1995 and 2006. Second, a minority of children (35.2%) 
prescribed ADHD medication are persistent with treatment at 6 months after initial 
medication prescription. Finally, initiating treatment with long-acting MPH as 
compared with the standard formulation was associated with persistence at 6 
months, after controlling for a range of child and clinical factors. 
Observed trends in the study cohort correspond to changes in how ADHD-
related disorders were diagnosed and treated over the study period in the UK.  The 
increase in the mean age at diagnosis may be related to the decline of the ICD-
based diagnosis of ‘hyperkinetic disorder’ and an increasing acceptance of the DSM-
IV ADHD diagnosis and treatment during this time,[82,87,105] the diagnostic criteria 
for the latter being less stringent in terms of the number and severity of 
symptoms.[27]  Less severe symptoms may be related to a higher age of 
diagnosis,[121] therefore an increase in age may be explained in part by trends in 
UK diagnostic practices. The observed shift in the type of medication prescribed may 
reflect changes in the medications available for ADHD over the study period.  
Following the relicensing of MPH for ADHD treatment in 1993,[105] long-acting MPH 
and atomoxetine became available for use in ADHD in 2002 and 2004[7] and the 
proportion treated with these latter medications increased thereafter. 
To our knowledge, this is the first study to examine ADHD treatment persistence 
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among UK children of all ages.  Notwithstanding differences between definitions of 
persistence, our study results, that a high proportion of children have a short initial 
treatment course parallel the findings of North American studies: a reported 50% of 
new users of MPH are persistent at 3 months[79]; and 47.4% are persistent at 6 
months.[70]  Similarly, 84% of children discontinued stimulant treatment by 2 months 
when the grace period was defined as 20% of the days supplied by the previous 
prescription.[9]  These estimates do vary somewhat from the study results, however 
all indicate that the majority of children who initiate treatment are not persistent for 
more than 6 months. 
The study results about periods of time between treatment courses suggest that 
a substantial proportion of children restart treatment soon after the end of the first 
treatment course, however many attempt to restart medication after long periods 
without treatment. Comparison between studies is again limited by the variation in 
the variable definitions, however multiple treatment courses, and restarting shortly 
(i.e. < 90 days) after as well as long after discontinuing initial treatment have been 
previously reported.[14,71,79] 
Discontinuation and reinitiation of ADHD medication treatment may be attributed 
to clinical reasons (e.g. changes in the need for symptom control in various settings 
(such as school vs. home vs. holidays), adverse effects or assessment 
purposes)[60] or reasons that are less clinically oriented (e.g. parental beliefs about 
medication, medication cost or inconvenient dosing).[73,111,122]  As 50-60% of 
children diagnosed with ADHD remain symptomatic during adolescence,[83] 
symptom resolution in the short term is not a likely explanation for most treatment 
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discontinuations.  Further research is warranted to understand the relative 
contribution of these factors to the observed patterns of medication persistence. 
The independent association between medication type and a higher proportion 
of children who persist with initial treatment beyond 6 months is consistent with 
recent literature.[78,79]  Children who are prescribed once-daily long-acting 
formulations of MPH may be more persistent with treatment as multiple-daily dosing 
generally involves dosing at school and the associated embarrassment in front of 
peers.[122]  Additionally, medication persistence may be enhanced because long-
acting formulations have a better effect on symptoms throughout the day.[123]  
Unmeasured differences in how and to whom the different formulations are 
prescribed may also confound this association. For example, clinicians may 
prescribe long-acting MPH to children with more severe symptoms, children who 
also may have more motivation to continue with treatment. However, regardless of 
medication type, most children were not persistent with treatment at 6 months. 
The results of this study should be considered in the context of the following 
limitations. Firstly, the exclusion of children not diagnosed with ADHD prior to 
medication prescription allowed better definition of the cohort as children diagnosed 
with ADHD but limits the generalizability of the results to children who have not been 
diagnosed at the start of treatment. Secondly, exclusion of children based on 
available follow-up time also limits generalization and may increase potential for 
selection bias. Thirdly, the lack of information about the diagnostic criteria used to 
assign ADHD codes allows for only general hypotheses to be made about the actual 
ADHD assessment practices used by GPs. Also, assumptions have been made 
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about the grace period used to define persistence with treatment. Varying the grace 
period to 60 or 90 days changed the proportion of children who were persistence (to 
56.9 and 68.5 respectively) but did not substantially change the result of which 
predictors were associated with persistence (Appendix F). In addition, since 
prescription records are not directly indicative of prescription filling or consumption, 
the measures in this study are only proxies for actual persistence with medication. 
Lastly, the results of this study reflect only primary care for ADHD. This study could 
not assess medication prescribed in secondary or tertiary care, or evaluate if 
variation in services for children (i.e. peadiatric psychiatrists), or the ability and 
willingness of GPs to refer for diagnosis affected the study results.[81,124] 
Conclusion 
This observational study of UK children with ADHD demonstrates that a minority 
of children (35%) who are prescribed ADHD medication persist with treatment 
beyond 6 months after initial medication prescription, suggesting that despite certain 
UK ADHD diagnostic and treatment practices, the majority of children with ADHD 
may be prescribed medication for shorter periods than needed for effective 
treatment over time. GPs should examine medication use patterns and be aware 
that suboptimal treatment outcomes may potentially be related to treatment 
discontinuation(s).[70]  Though type of medication may be independently associated 
with persistence, treatment persistence is likely maximized by factors such as 
symptom severity and parental attitudes toward medication. Future observational 
studies evaluating ADHD medication in primary care settings should take into 
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account the reported poor persistence with pharmacological treatment among 
children with ADHD.  
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Table 5.1. Demographic and clinical characteristics of children diagnosed with Attention 
Deficit Hyperactivity Disorder in the UK (n=3414) by treatment status*, 1994-2006 
 
 
Overall 
n (%) 
Untreated 
n (%) 
Treated 
n (%) 
 2910 (100) 1596 (54.8) 1314 (45.2) 
Follow up time   
(mean (SD†), years)  
11.6 (4.0) 11.4 (4.0) 11.7 (4.1) 
Gender 
   
  Male 2454 (84.3) 1333 (83.5) 1121 (85.3) 
  Female 456 (15.7) 263 (16.5) 193  (14.7) 
Age group at diagnosis  
(years) 
   
  1-5 500 (18.2) 234 (23.8) 28 (9.2) 
  6-9 1319 (45.3) 675 (42.3) 644 (49.0) 
  10-14 959 (33.0) 457 (28.6) 502 (38.2) 
  15-18 132 (4.5) 85 (5.3) 47 (3.6) 
Year of diagnosis  
   
1993 – 2001 713 (24.5) 404 (25.3) 309 (23.5) 
 2002 – 2006 2197 (75.5) 1192 (74.7) 1005 (76.5 
Socioeconomic status  
(Townsend Index ‡, quintile) 
   
   1 (least deprived) 495 (18.3) 275 (18.6) 220 (17.9) 
   2  439 (16.2) 264 (17.8) 175 (14.3) 
   3  545 (20.1) 276 (18.6) 269 (21.9) 
   4 695 (25.7) 389 (26.3) 306 (24.9) 
   5 (most deprived) 534 (19.7) 277 (18.7) 257 (20.9) 
Psychiatric comorbidity  
prior to ADHD diagnosis § 
   
   Anxiety  14 (0.5) 5 (0.3) 9 (0.7) 
   Depression 12 (0.4) 7 (0.4) 5 (0.4) 
   Conduct disorder 10 (0.3) 4 (0.3) 6 (0.5) 
   No comorbidity 2874 (98.8) 1580 (99.2) 1294 (98.5) 
Specialist contact on diagnosis day || 
   
No 1536 (52.8) 771 (48.3) 825 (58.2) 
Yes 1374 (47.2) 825 (51.7) 549 (41.8) 
* Percentage of children diagnosed with ADHD with at least one prescription record for ADHD 
medication  
† SD, standard deviation 
‡ Socioeconomic status was measured using the Townsend index, which is based on the postal code 
of a patient’s home address.[120] 
§ Psychiatric comorbidity was defined as the presence of an anxiety, depression or conduct disorder 
Read code at least once prior to the diagnosis date.  
|| Evidence of specialist involvement was determined by the source of the initial ADHD diagnosis 
records (e.g. from a specialist or hospital consultant) or the presence of records for referrals made or 
consultant letters received on the initial diagnosis date.  
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Table 5.2: Selected predictors of initial treatment course length of at least 6 months among 
children with ADHD in the UK (n=1314) 
 
 
N=1314 
n (%)* 
Adjusted Risk 
Ratio† 
95% Confidence IntervaI 
(CI) 
Overall  464 (35.3)   
Gender 
   
  Female 58 (30.1) 0.9 0.7, 1.1 
  Male 406 (36.2) 1 Reference‡ 
Age group at diagnosis (years) 
   
  1-5 42 (34.7) 1.0 0.6, 1.7 
  6-9 232 (36.0) 1 Reference 
 10-14 178 (35.5) 0.8 0.7, 1.0 
 15-18 12 (25.5) 0.7 0.4, 1.2 
Year of diagnosis 
   
1993 - 2001 78 (25.2) 1 Reference 
 2002 - 2006 386 (38.4) 1.4 1.1, 1.7 
Socioeconomic status (Townsend 
Index, quintile) 
   
   1 (least deprived) 88 (28.0) 1.0 0.8, 1.2 
   2 49 (32.3) 0.8 0.6, 1.0 
   3 87 (32.3) 0.9 0.7, 1.1 
   4 112 (36.6) 1.0 0.8, 1.2 
   5 (most deprived) 100 (38.9) 1 Reference 
Comorbidities 
   
   Anxiety disorders 5 (55.6) 1.8 0.7, 4.6 
   Depression disorders 1 (20.0) 0.9 0.2, 4.2 
   Conduct disorders 1 (16.7) 1.0 0.1, 2.1 
   No comorbidity 457 (35.3) 1 Reference 
Specialist contact on diagnosis 
day 
   
   Yes 186 (33.9) 1.0 0.8, 1.1 
   No 278 (36.3) 1 Reference 
First drug type 
   
   Dexamphetamine 7 (33.3) 1.0 0.6, 1.9 
   Atomoxetine 23 (41.4) 1.3 0.9, 1.7 
   Long-acting MPH § 144 (41.6) 1.2 1.1, 1.4 
   MPH 290 (32.5) 1 Reference 
Time from diagnosis to medication 
initiation 
   
   0 (same day as diagnosis) 94 (36.4) 1 Reference 
   1-30 days 95 (40.6) 1.1 0.9, 1.4 
   31-60 days 51 (39.5) 1.0 0.7, 1.3 
   61-90 days 35 (38.8) 1.0 0.7, 1.3 
   91-120 days 32 (36.8) 1.0 0.7, 1.3 
   121-180 days 48 (36.1) 0.9 0.7, 1.1 
   181-365 days 66 (31.4) 0.9 0.7, 1.1 
   1-2 years 43 (24.9) 0.7 0.5, 0.9 
* Proportion of children within each category who were persistent with initial medication treatment for 
at least 6 months. 
† Adjusted for all other factors in the table. A risk ratio greater than 1 indicates an increased ‘risk’ of 
continuing initial treatment beyond 6 months as compared with the reference group. 
‡ Reference=reference category 
§ MPH, methylphenidate 
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V.  RESULTS: Stimulant treatment and injury among children with Attention 
Deficit Hyperactivity Disorder:  an application of the self-controlled case series 
study design2 
 
A.  INTRODUCTION  
 Attention deficit hyperactivity disorder (ADHD) in childhood is characterized 
by inattention, hyperactivity and impulsivity.  Children with ADHD experience high 
rates of injuries, including fractures, head injury and burns.[17-19]  While stimulant 
medications for the treatment of ADHD such as methylphenidate (MPH) have been 
shown to reduce core symptoms and improve both school performance and family 
interactions,[20] it is unclear if treatment also affects injury risk.  
 Stimulant medication use is hypothesized to decrease injury risk by 
reducing ADHD symptoms such as inattention or impulsivity.  Conversely, periods of 
medication non-use may increase risk for injury.[21,22]  Previous clinical trials have 
reported too few injuries to evaluate these hypotheses.[25]  Among children treated 
with MPH, one observational study showed that use of long-acting MPH was 
associated with a lower odds of injury compared with use of standard formulation 
MPH.[16]  Injury rates were slightly lower among children who were adherent 
stimulant users compared with those who were less adherent.[26]  Although both 
studies suggest that overall exposure to stimulant medication use may be protective 
                                                        
2 This chapter will be submitted for publication to a peer-reviewed journal. Authors 
include those listed on the title page. 
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for injuries, confounding due to uncontrolled between-group factors cannot be 
eliminated.  For example, a high level of parental supervision that may avert child 
injury may be associated with more diligent healthcare-seeking and better adherence 
to medication, creating a spurious association.  Since factors such as adherence to 
medication varies between families, better control of individual-level confounders can 
be obtained using a study design in which a child’s untreated time is used as 
unexposed time (rather than using untreated children as the unexposed group).    
 The current study assesses the association between stimulant medication 
use and risk of injury, using a self-controlled case series method.[125]  The self-
controlled case series design takes advantage of the intermittent periods of 
medication use that characterize stimulant medication patterns in children with ADHD 
to make within-individual comparisons of injury risk between time periods on and off 
stimulant medications. The unit of analysis is an individual person, therefore the 
analysis cannot be confounded by individual characteristics that are stable over time 
(e.g. sex, genetics).  We hypothesize that injury risk among children with ADHD is 
decreased during stimulant treatment periods compared with untreated periods. 
 
B.  METHODS 
Study Population  
This study was conducted using data from The Health Improvement Network 
(THIN) from January 1st, 1993 to June 30th, 2008.  General practices (GP) in the UK 
that use Vision clinical computer systems provide THIN with information to about 
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general practice visits, the date and details of prescriptions and referrals for care 
received in secondary care facilities.[100]   
Cases were selected from patients who were registered with a THIN practice, 
had a diagnosis of ADHD, experienced a first-ever incident injury event, and who had 
been prescribed stimulant medication at least once between the ages of 1 and 18 
years during the study period.  When a patient registers with a new practice, 
diagnoses and events that are part of the patient’s history may be recorded using the 
date that the information is entered into the computer, not the date of the event.  
Therefore, only diagnoses and injury events after the first year of registration were 
included to ensure that only incident events were captured.  Observation time started 
on the day of initial ADHD diagnosis and continued until the day the child turned 19 
years old, died, transferred out of the practice or the last date of data collection from 
the practice (whichever was earliest). 
Information in THIN is coded using the Read clinical classification system.  
The Read codes used to define ADHD included any code that referred specifically to 
ADHD, attention deficit disorder (ADD) or hyperkinetic disorder, plus the 2 codes 
most commonly used to identify ADHD in THIN (Appendix B.1). 
Injury Outcome 
The outcome of interest, medically-attended injury, was defined using data 
available in THIN regarding the date and location of service (general practice, 
emergency room or hospital), and procedures or referrals made as a result of a visit 
for an injury.  Medically-attended injuries were defined as a record that described 
bodily harm with an injury and poisoning Read code.  Injury Read codes are 
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classified by type into 27 subgroups.  All injury types were included except for ‘late 
effects of injury or poisoning events’ and ‘medical/surgical procedures causing 
complications’.  
Exposure to Medication  
Methylphenidate (MPH) and dexamphetamine were the only types of stimulant 
medications approved for ADHD treatment in the UK during the study period.[69]  
Records of all formulations and strengths of both medication types were included in 
the assessment of exposure status.  
Assessment of stimulant medication treatment periods required the 
determination of the treatment length for each prescription (i.e. the days supply).  The 
days supply value was calculated from the daily dose and quantity prescribed 
whenever possible (55% of all prescriptions).  For over half (55%) of these 
prescriptions with non-missing values, the days supply was 30 days (82% were 
between 28 and 32 days).  Therefore, days supply values were set to 30 days for 
prescriptions where either dose or quantity prescribed was missing (45% of all 
prescriptions).  A 30 day supply is also the recommended prescription length for 
controlled drugs (such as stimulant medication) in the UK.[110]   
Starting from the date of diagnosis, all available observation time was 
categorized as either treated or untreated.  A treatment period started on the day a 
stimulant was prescribed and extended until the end of the days supply value plus a 
30 day grace period.  Untreated periods were all observation time that was not 
classified as treated.  Each child could have multiple treated and untreated periods.  
To assess for differences in the effect of medication according to the time since the 
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start of the treatment course, observation time during the first 30 days of each 
treatment course were classified separately from observation time occurring after the 
30th day of treatment.  Untreated time prior to medication initiation was also classified 
separately from between-treatment and post-treatment time (Figure 6.1). 
The length of the grace period used to classify treatment periods may be 
based on the medication half-life, clinical efficacy and/or as a set multiple of the 
number of days of medication supplied by the previous prescription.[13]  A 30-day 
grace period was chosen so that children who take medication only during the school 
week would not be misclassified as having discontinued treatment.  Additionally, a 
30-day grace period has previously been used to examine patterns of ADHD 
medication use in administrative data.[78,79,108]   
Application of the self-controlled case series method 
As stated above, the self-controlled case series design was used in order to 
control for individual-level time-independent factors that might confound the stimulant 
treatment-injury association, such as parental supervision and care-seeking behavior.  
There are three relevant methodological considerations when applying the self-
controlled case series design.  First, while the design controls for confounding by 
factors that are stable over time, time-varying risk factors for the outcome within an 
individual may lead to within-person confounding.  Therefore, two strong risk factors 
for injury, age (by age group, 1-5, 6-10, 11-14, 15-18 years) and season (winter, 
spring, summer, autumn) were controlled for in the analyses.  Second, events must 
be independent within a person, an assumption that probably does not hold with 
injuries as the occurrence of an injury may increase the risk of a subsequent 
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injury.[115]  Thus this study includes only the first injury event in the analysis.[116]  
Finally, an assumption of the self-controlled case series is that the treatment at any 
time point is not affected by the occurrence of the event at a prior time point.  In this 
study, there was concern that a medically-attended injury may precipitate the initial 
prescription of medication among children with ADHD.  We assessed the distribution 
of injuries in the 6 months prior to initial medication prescription and found no 
indication that injury events precipitate initial medication (Figure 6.2).  Therefore all 
person-time between diagnosis and initial medication prescription was included in the 
analysis.   
Analysis 
The primary analysis assessed the impact of stimulant medication on the 
occurrence of first incident injury by comparing the rate of events during all periods of 
treatment with stimulant medication to the rate during all untreated time periods.  
Self-controlled incident rate ratios (IRR) and their 95% confidence intervals (CI) were 
estimated using conditional Poisson regression.  We assessed estimate precision 
using confidence limit ratios (CLR).[126]  All data were analyzed using SAS version 
9.2 (SAS Institute Inc, Cary, NC, USA). 
Stratified analyses were conducted to assess the association between 
stimulant medication and injury events by gender, age group and type of medication.  
Sensitivity analyses 
i. Medically-attended injury: We performed several sensitivity analyses using 
different definitions for injury events.  Types of injuries that were hypothesized 
to be more consistently medically-attended (upper limb, lower limb and skull 
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fractures, head injuries) were examined separately. Injuries were also 
stratified by the day of the week (weekend or weekday).  
ii. Definition of ADHD: The broadening of the diagnostic criteria for ADHD and 
the associated increase in stimulant treatment for ADHD in recent years may 
modify the association under study.  Children treated with stimulants before 
and after the year 2000 were therefore analyzed separately. 
iii. Assumptions of the study design: The results of self-controlled case series 
may be biased by incorrect specification of the treatment period and by the 
inclusion of events that alter the distribution of post-event treatments. 
Sensitivity analyses were undertaken to determine if the results were 
influenced by (i) varying the length of the grace period used to determine 
treatment course length (e.g. 15, 45, 60, 90 days), (ii) excluding untreated 
person-time prior to medication initiation or (iii) excluding fatal injuries that 
obviously precluded post-event treatment. 
Further analyses and results comparing the self-controlled case series method 
to traditional cohort analyses are contained in Appendix G.  
The University of North Carolina Public Heath and Nursing Institutional Ethics 
Review Board approved the study protocol. 
 
C.  RESULTS 
From 4234 eligible children diagnosed with ADHD identified in THIN data, 328 
children had an incident injury event after initial ADHD diagnosis and at least one 
prescription for stimulant medication.  This group of 328 children was analysed using 
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the self-controlled case series design.  This population was predominantly male 
(86.9%, n=285).  The mean age at ADHD diagnosis was 9.7 years (standard 
deviation (SD): 3.0).  The mean person-years of observation per child was 5.9 years 
(SD: 2.7).  
The initial type of medication prescribed was methylphenidate (MPH) for 
98.5% (n=323); 76.8% (n=252) were prescribed standard formulation MPH, 21.7.0% 
(n=71) long-acting MPH (Table 6.1).  Using a 30-day grace period to define the end 
of treatment periods, 23.8% had a single treatment period; 46.0% had 2 to 5 
treatment periods, 20.1% had between 6 and 10 treatment periods and 9.1% had 
more than 10 treatment periods. 
Common types of injuries included upper limb fractures, head injuries (i.e. 
‘intracranial injuries excluding skull fractures’), other upper and lower extremity 
injuries, superficial injuries, and sprains and strains.  Fractures occurred in 24.4% 
(n=80) of the study group. Head injuries (not including skull fractures) occurred in 
14.0% (n=46) of the study group (Table 6.2). 
The unadjusted incident rate ratio (IRR) for an injury event comparing 
treatment periods to all untreated periods was 0.70 (95% confidence interval (CI): 
0.53, 0.94; CLR: 1.77).  Adjustment for age group at start of treatment and season 
did not appreciably change the estimate [IRR= 0.70; (95%CI): 0.52, 0.93, CLR: 1.80]. 
The rate of injury was lower during the first 30 days of any stimulant [IRR 
(95%CI), CLR: 0.64 (0.39, 1.05), CLR: 2.70] and after the first 30 days of any 
stimulant treatment course [IRR (95%CI), CLR: 0.71 (0.52, 0.97); CLR: 1.86]. 
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In subgroup analyses, there was stronger evidence of a protective association 
between medication and injury among boys (IRR= 0.66; 95%CI: 0.48, 0.91; CLR: 
1.88) than among girls (IRR= 0.98; 95%CI: 0.44, 2.10; CLR: 4.82).  Age group 
estimates yielded similar findings with less precision, however the effect was most 
pronounced for children age 1 to 5 (IRR= 0.52; 95%CI: 0.11, 2.48; CLR: 23.15) and 
age 10 to 14 (IRR= 0.62; 95%CI: 0.39, 0.97; CLR: 2.45) (Table 6.3).  
Estimates stratified by injury type, day of injury, and period of time (pre or post 
2000) were all similar to the main estimate, except for the estimate for head injury 
(IRR= 1.18; 95%CI: 0.56, 2.48, CLR: 4.41).  Excluding 5 children who were initially 
treated with dexamphetamine did not change the IRR (IRR= 0.71; 95%CI: 0.53, 0.95; 
CLR: 1.80). Excluding post-diagnosis untreated time prior to medication initiation 
yielded a slightly higher estimate (IRR= 0.82; 95%CI: 0.58, 1.17; CLR: 2.04).  
The results did not change substantially when the length of the grace period was 
varied (15, 45, 60, and 90 days) or when the one child who died as a result of an 
injury event was excluded (Table 6.4). 
Appendix H Table H.1 presents the results about unexposed periods differently. 
D. DISCUSSION 
In this study, stimulant medication was associated with a decreased risk of injury 
in children treated for ADHD.  The protective association is consistent across most 
subgroups, except for gender, where the effect was present in boys but sample size 
limited our ability to make conclusions about girls.  The estimates for all types of 
injury were protective, except for head injury.  The injury rate was decreased during 
treatment periods both within the first 30 days of a treatment course and in the 
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remainder of the treatment course.  Injury rates during untreated periods after initial 
medication prescription were lower than injury rates prior to medication prescription. 
The results support the hypothesis that treating the core symptoms of ADHD with 
medication can decrease injury risk.  We were not able to conclude that medication 
had an effect in girls as we had low number of female injuries and thus less precision 
for the analysis of girls.  A difference in the effect of medication is plausible as there 
are gender differences in injury experiences and ADHD diagnosis.  The increased 
rates of all types of injuries among boys as compared with girls across all ages has 
been attributed to a complex interaction of behavioral, environmental and social 
factors.[127,128]  Information about type and severity of ADHD symptoms was not 
available in this study however it is possible, if the distribution of symptoms and/or 
types of injuries varies by gender, that the association between stimulant medication 
and injury risk may also be different between genders. 
The protective effect of medication in both the initial 30 days and in the later 
portion of each treatment course indicates that the effects of stimulant medication are 
constant over time on treatment.  Benefits of medication may extend to untreated 
periods either between or after medication use as indicated by lower injury rates 
during these untreated periods as compared with pre-medication periods.  This is 
consistent with research that suggests that medication effects may be indirect by 
facilitating improved function at home and school over time.[65]  Another 
consideration is that parents are skilled judges of the effects of medication and 
remove children from medication at times when symptoms are not as problematic or 
are controlled from non-medication sources. 
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Our study examined whether stimulant medication had an acute effect on injury 
risk among children with ADHD.  Two related studies focused on slightly different 
dimensions of the association between stimulant medication use and injury risk.  In 
comparing children by stimulant medication type, long-acting MPH was associated 
with fewer outpatient visits or hospitalizations for injuries as compared with the 
standard formulation of MPH.[16]  In a second study, Marcus et al. assessed injury 
risk among stimulant treated children over a single treatment course of at least 4 
months.  Children who were more adherent to medication were less likely to 
experience an injury [injuries/person-year: 0.227; 95%CI: 0.214, 0.240) vs. 0.230; 
95%CI: 0.204, 0.254), adjusted hazard ratio 0.89, p= 0.07].[26]  Both studies 
compared different groups of children and thus attempted to control for relevant child-
level confounders, however the use of administrative data limited the measurement 
of confounders that may have been relevant to medication use/prescription and injury 
such as family functioning (i.e. level of supervision), healthcare-seeking behavior or 
ADHD severity.  
This study was able to build upon the previous literature to examine injury rates 
for children with ADHD during periods on and off medication, the injury rates 
immediately following diagnosis prior to medication initiation and assess injury risk 
over different periods of treatment.  The key strength of the self-controlled case 
series design is that the results are perfectly controlled by design for time-invariant 
differences between individuals.  This study design is especially relevant to children 
with ADHD, since stimulant medication prescription and use within an individual is 
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influenced by many family and social factors and because medication use in this 
population is characterized by intermittent periods of treatment.  
Confounding could nevertheless occur in the self-controlled case series design if 
a factor was associated with both the timing or duration of treatment periods and risk 
of injury (such as a change in school environment or non-pharmacological 
treatments).  These factors would require a large effect on injury risk among many 
children within the study group to substantially affect these findings.  However future 
research should examine the distribution and effect of these factors to determine their 
impact on this association.  
Some medically attended injury events may not have been recorded in THIN 
data, for example, injuries that were attended to in after-hours clinics that were not 
reported to the child’s GP.  This limitation would reduce sample size, however in 
order to bias the study results, these injured children would have to differ 
systematically in their medication treatment patterns from the study participants. 
The unexpected finding regarding head injuries may reflect another study 
limitation.  The Read codes for injury have not been validated, therefore it is not 
known how the codes are assigned in practice.  In this case, head injury Read codes 
may reflect a GP visit for a suspected head injury rather than an actual injury.  This 
outcome misclassification may have affected the head injury estimate. 
This study was able to take advantage of the detailed prescription information to 
characterize treatment periods.  However, prescription records are only a proxy for 
prescription dispensing and actual consumption and do not necessarily indicate 
exposure to stimulant medication on a given day during the observation period. 
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Despite the use of a large healthcare database, the self-controlled design limited 
our ability to examine injuries by type, severity or cause.  Future research could 
utilize more detailed injury information in an even larger sample to provide insight 
about the types of injuries that are affected by stimulant medication use among 
children with ADHD.  The results of this self-controlled case study can be generalized 
to injured children with ADHD that were treated with stimulants at least once.  The 
results do not address whether treatment would have an effect on injury risk among 
children who have never received treatment. 
Conclusions 
 This study supports the clinical hypothesis that current stimulant medication use 
may reduce risk of injury among children with ADHD.  These findings are important 
for care and treatment of children with ADHD treated with stimulants.  Up to 15% of 
children in the UK experience a medically-attended injury each year[36] and children 
with ADHD experience a disproportional number of these injuries.[18]  Continued 
stimulant medication treatment may be able to prevent injuries and the resulting 
impairments in this high-risk group (children with ADHD treated with stimulants at 
least once).  This analysis cannot answer the question of whether injury risk can be 
reduce by stimulant medication initiation in children with ADHD not previously 
treated. Additionally, recent treatment guidelines support the continuous use of 
medication, recognizing that there are additional benefits of medication for family 
relationships and participation in non-school activities.[61]  Consideration of the 
potential benefit of continuous stimulant medication on injury risk may aid clinicians 
and families in decision-making about continuation of stimulant medication in children 
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who have already been treated. 
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Figure 6.1: Graphical representation of the classification of observation time in 
this self-controlled case study 
 
 
Figure 6.1 represents the self-controlled case series study design for a single individual prescribed 
medication.  Injury could occur in either treated or untreated periods.  Rate ratios are pooled 
estimates comparing the rate of injury events during treated periods divided by the rate of events 
during untreated periods. Unexposed person-time can occur prior to the first medication prescription 
or after the first medication prescription. 
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Table 6.1: Description of study population: Children with ADHD who have at least 1 
prescription for stimulant medication and an incident injury event (n=328) 
 
 
*Treated time - follow-up time (child-years) with exposure to stimulant medication  
Untreated time – follow-up time (child-years) without exposure to stimulant medication 
† The self-controlled case study (SCCS) method requires that only children who have experienced 
the outcome and the treated contribute person-time to the relative incidence rate estimates.  These 
events and person-time values cannot be used to calculate meaningful absolute incidence rates.  
Group Injuries 
n (%) 
Injuries on 
treatment* 
Total 
treatment 
time (child-
years) 
Injuries 
while 
untreated 
Total 
untreated 
time (child-
years)† 
All stimulants 328 
(100.0) 
139 885.4 189 1041.8 
Gender 
     
Male 285 (86.9) 117 778.8 168 934.6 
Female 43 (13.1) 22 106.6 21 107.2 
Age at initial 
prescription 
(years) 
     
1-5 10 (3.1) 6 48.8 4 20.6 
6-9 151 (46.0) 70 541.7 81 451.5 
10-14 140 (42.7) 47 274.0 93 483.1 
15-18 27 (8.2) 5 20.9 22 86.7 
Initial medication 
type 
     
MPH  252 (76.8) 93 742.4 159 842.8 
Long acting MPH  71 (21.7) 27 131.1 44 181.3 
Dexamphetamine 5 (1.5) 0 12.8 5 17.7 
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Table 6.2: Types of injury events as classified by Read code subchapters 
 
 
*Other includes: dislocations and subluxations, open wound of lower limb, non-medicinal agent toxic 
effects 
 
 n (%) 
 Fracture of upper limb 51 (15.6) 
 Intracranial injuries excluding skull fracture 46 (14.0) 
 Traumatic complications/unspecified injury 45 (13.7) 
 Sprains and strains  37 (11.3) 
 Superficial injury (abrasions, blisters, stings, bites) 26 (11.0) 
 Contusion (bruise) and intact skin 27 (8.3) 
 Fracture of lower limb 23 (7.0) 
 Open wound head/neck/trunk 17 (5.2) 
 Poisoning (medicinal agent) 9 (2.7) 
 Open wound of upper limb 8 (2.4) 
 Fracture of skull 6 (1.8) 
 Crushing injury 4 (1.2) 
 Foreign body in orifice 4 (1.2) 
 Burns 4 (1.2) 
 Other* 11 (4.2) 
Total 328 (100) 
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Table 6.3: Self-controlled case series analyses for the association between stimulant 
medication treatment and first medically-attended injury event, stratified by case 
characteristics  
 
*IRR, incident rate ratio; CI, confidence interval; CLR, confidence limit ratio (upper confidence 
limit/lower confidence limit).  The IRR estimates the rate ratio of injury comparing treated periods to 
untreated periods.  All estimates are self-controlled and additionally adjusted for age group and 
season, except age group estimates, which are adjusted for season only. 
 
Cases in 
analysis 
(n) 
Adjusted IRR 
(95%CI)* 
CLR* 
All stimulants 328 0.70 (0.52, 0.93) 1.79 
 
   
Gender 
   
Males 285 0.66 (0.48, 0.91) 1.88 
Females 43 0.98 (0.44, 2.14) 4.82 
Age at initial prescription 
(years) 
   
1-5 10 0.52 (0.11, 2.48)  23.15 
6-9 151 0.78 (0.52, 1.18) 2.26 
10-14 140 0.62 (0.39, 0.97) 2.45 
15-18 27 0.85 (0.28, 2.56) 9.01 
Initial medication type 
   
MPH  252 0.72 (0.52, 1.01) 1.94 
Long-acting MPH  71 0.71 (0.37, 1.39) 3.74 
Dexamphetamine 5 n/a  
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Table 6.4: Results of sensitivity analyses 
 
*IRR, incident rate ratio; CI, confidence interval; CLR, confidence limit ratio (upper confidence 
limit/lower confidence limit).  The IRR estimates the relative rate of injury comparing treated periods 
to untreated periods.  All estimates are self-controlled and additionally adjusted for age group and 
season, except age group estimates, which are adjusted for season only 
† Fractures include injuries coded as ‘fracture of upper limb’, ‘fracture of lower limb’ and ‘fracture of 
skull’.  
‡ Head injuries include injuries coded as ‘intracranial injuries excluding skull fracture’ 
 
 
 
 
 
Cases in 
analysis 
n 
Adjusted IRR 
(95%CI)* 
CLR* 
    
All stimulants 328 0.70 (0.52, 0.93) 1.79 
 
   
Injury type 
   
Fracture † 80 0.71 (0.39, 1.28) 3.25 
Head injury ‡ 46 1.18 (0.56, 2.48) 4.41 
Other type of injury 202 0.61 (0.42, 0.90) 2.15 
 
   
Day of injury 
   
Weekend injury 44 0.50 (0.23, 1.12) 4.94 
Weekday injury 284 0.72 (0.53, 0.99) 1.88 
    
Year of medication 
initiation 
   
<2000 110 0.69 (0.42, 1.12) 2.67 
>2000 218 0.70 (0.49, 1.01) 2.07 
 
   
Grace period (days) 
   
15 328 0.69 (0.52, 0.92) 1.79 
45 328 0.69 (0.52, 0.93) 1.80 
60 328 0.70 (0.52, 0.95) 1.80 
90 328 0.74 (0.55, 0.99) 1.81 
    
Exclusion of untreated 
time prior to medication 
initiation 
256 0.82 (0.58, 1.17) 2.04 
    
Exclusion of fatal events 327 0.70 (0.53, 0.94) 1.80 
 
   
Exclusion of children who 
initiated treatment with 
dexamphetamine 
323 0.71 (0.53, 0.95) 1.80 
  
 
 
 
 
 
VII.  DISCUSSION 
A.  SUMMARY OF FINDINGS 
This dissertation examined the use of medication and injury outcomes among 
children with ADHD using information from a large database of primary care records.  
The research had two main objectives: 1) To examine the patterns of ADHD 
medication use, specifically the length of time on initial medication treatment and the 
independent predictors of medication persistence at 6 months after medication 
initiation (Specific Aim 1) and 2) to examine the association between stimulant 
medication use and risk for injury among children with ADHD by comparing injury 
rates during periods of stimulant medication use to rates during untreated periods 
(Specific Aim 2).  
To address the first objective, patterns of medication use among children 
diagnosed with ADHD were described.  Results showed that only about one-third of 
children (35.2%) prescribed ADHD medication were persistent with treatment at 6 
months after initial medication prescription.  Initiating treatment with long-acting 
methylphenidate as compared with the standard formulation of methylphenidate was 
associated with increased persistence at 6 months, after controlling for a range of 
child and clinical factors.  Further research is needed to explore the exact reasons 
for the observed patterns of medication use, however the results highlight the 
potential that treatment for a large subgroup of children with ADHD may be 
suboptimal, rendering children at risk for poor ADHD-associated outcomes. 
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To address the second objective, the association between stimulant medication 
use and injury outcomes was assessed using a self-controlled case series method to 
compare injury rates during periods of medication use to injury rates during 
untreated periods.  Periods of stimulant medication use were associated with a lower 
rate of injury and the association was clearly observed among boys.  The effect of 
stimulant medication did not decline substantially after the first 30 days of a 
treatment course.  Findings were similar when the exposure classification was varied 
and when fatal injuries were excluded.  These findings 1) add evidence to the small 
but growing body of empirical literature that support that stimulant medication may 
be protective for injury, likely by reducing symptoms that are also risk factors for 
injury and 2) suggest that injury outcomes should be considered as clinicians and 
families engage in decision-making about initiation or continuation of stimulant 
medication. 
The results from the first research aim had an important implication for the 
design and conduct of the second research aim; if medication use is suboptimal (in 
duration or continuity), the benefits of medication are unlikely to be easily evaluated.  
The results confirmed that the method chosen to assess the effect of stimulant 
medication in Specific Aim 2 needed to consider the short and intermittent nature of 
medication use among children with ADHD.  
 
B.  PUBLIC HEALTH IMPLICATIONS 
The results of this dissertation research have several implications for public 
health and clinical practice.  Firstly, the finding that initial ADHD medication 
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treatment is relatively short and that treatment is intermittent over time suggests that 
clinicians need to monitor children treated with medications closely, probe for 
contributing reasons if medication is discontinued and provide support to families 
and patients to continue treatment when appropriate.  In the clinical setting, if only 
35% of children are persistent at six months, clinicians (and families and children) 
will not be able to judge the effect of medication over the long term and ultimately, 
any beneficial effects of treatment cannot be realized.  Given that ADHD is a chronic 
condition that generally extends into adolescence and adulthood,[83] these results 
indicate that a substantial proportion of this clinical group may be possibly 
undertreated and thus potentially at risk for the myriad of poor ADHD-associated 
long-term academic, psychosocial and health outcomes. 
Additionally, pediatricians and psychiatrists in the UK are becoming 
overburdened with the ongoing care of children with ADHD and there is an 
increasing need for general practitioners (GPs) to play an important part in the 
management of ADHD.[81]  These results will contribute to the understanding of 
how children with ADHD are treated by GPs.  In clinical research settings, stimulant 
treatment is effective for symptom reduction for up to 80% of children with ADHD.  
Though patient-level factors such as a change in the need for symptom control over 
time may partially explain the study findings about medication persistence, factors 
relevant to GPs in the community setting, such as the availability of behavioral 
interventions or clinician knowledge and ability to provide support to families with 
ADHD may also be influential.  These results therefore may inform GPs about 
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current community practice, and also provide the basis for future research about the 
utility of medication use patterns as an indicator of quality of care in primary care. 
Although recent treatment recommendations support continuous use of 
medication,[61] stimulant medication use is often discontinued during weekends and 
holidays due to concerns about negative long-term effects of stimulant use (e.g. 
reduced appetite and growth).[98,99]  These results indicated that injury should be 
added to the list of potential benefits of medication use.  Assuming that though injury 
rates may be relatively lower during periods between treatments than while on 
treatment, rates may still be higher than children without ADHD.  Thus, if medication 
is discontinued for short periods of time, clinicians can advise that preventive 
actions, such as increased supervision, be taken to minimize injury risk during this 
period. 
Injury is an important preventable outcome among children with ADHD.  The 
results suggest treatment of ADHD with stimulant medication treatment may 
decrease the disproportionally increased risk for injury risk among children with 
ADHD.  Effective treatment, including stimulant medication, may be able to prevent 
injuries as well as the potential injury sequelae that can greatly impact development 
and family functioning.  This can contribute to improved outcomes for children and 
their families while reducing burden on the health care system over the long term. 
These results also have relevance to injury prevention research, by contributing 
to the large body of injury research examining behavioral risk factors such as 
impulsivity and inattention.  Practically, research examining pediatric injury should 
consider ADHD and ADHD stimulant treatment as a potential effect modifier.  
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This study examined children with ADHD who had contact with primary care 
providers, however it is likely that the public health impact of results from both 
research results have relevance to the larger population of children.  ADHD is likely 
under-diagnosed in the UK.  In 1999, it was estimated that approximately 65% (49 
000) of children with ADHD had not been identified or treated.[87]  As the diagnosis 
and treatment of ADHD improves,[82] the results of this research will become 
applicable to a larger group of children. 
 
C.  STRENGTHS 
Use of the THIN data 
A strength of this research is the use of THIN data.  The database is large, 
longitudinal and based on health care received from GPs in the community setting.  
In particular the prescription records are detailed and very comprehensive, as GPs 
use electronic prescribing and are responsible for most prescriptions in the UK. The 
majority of prescriptions are directly included in the database, since the GP 
generates the patient copy of the prescription by computerized entry. In the UK 
context, stimulant medication prescriptions are generally given for 30 days and 
patients need to contact the GP for refills and further prescriptions. This ongoing GP 
contact is reflected in THIN and allowed for better understanding of which 
prescriptions are more likely to have been filled than previous research using this 
type of database. The nature of the database and the comprehensive data on the 
timing of medication prescriptions allowed for the examination of long periods of time 
and the detailed characterization of prescription patterns in this research.  The long 
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observation periods available increased the number of injuries ascertained and thus 
increased the sample size for the self-controlled case study.  Additionally, the nature 
of prescription data allowed the precise measurement of timing of medication 
exposure that was necessary to appropriately apply the self-controlled case series 
method. 
Since the incidence and prevalence of ADHD is relatively low in the UK, most 
previous studies about health care of children with ADHD have been conducted in 
small geographic areas with small study samples.  The size of this database allowed 
the selection of a larger number of children with ADHD with the added benefit of 
being representative of the UK population in terms of age, gender and region.  This 
research also has fewer limitations to generalizability of the results because of the 
universal structure of the UK health system. 
Study design (Specific Aim 2) 
Previous studies about the association between medication use and injury 
among children with ADHD compared groups of children by type of medication or 
overall adherence to medication, thus potentially being affected by the common 
pharmacoepidemiology problem of confounding by factors that are difficulty to 
measure in large databases.  Use of the self-controlled case series allowed for an 
estimate of the association between stimulant medication and injury that avoided 
confounding by factors that have a stable effect on the association over time.  
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D. LIMITATIONS 
Definition of ADHD 
The definition of ADHD was based on a process developed specifically for this 
research and did not include a validation process.  The criteria used by each 
physician to assign ADHD Read codes are not known and are likely to vary 
substantially.  A range of codes were used in this research to attempt to capture 
ADHD over the study period, however it is possible that children with ADHD were 
misclassified as a result of GP coding practices or the ADHD definition used in this 
research.  As the code list that defined ADHD was more inclusive than previous 
studies,[101,129] this limitation may have increased the size of our sample, and 
affected our estimates, particularly estimates of proportion of children with ADHD 
who were treated with medication.  The lack of a validated ADHD definition in 
conjunction with the limitations of code-based diagnoses also resulted in the inability 
to examine the influence of type or severity of ADHD in this research. 
Assessment of injury outcomes 
Injury information in THIN has not been validated.  Injury information is likely 
comprehensive for injuries that are medically-attended in the GP office.  The 
recording in THIN of injuries that are medically-attended in another location (hospital 
or emergency room) relies on the transfer of information to the GP and thus it is 
possible injury events were under-ascertained in this research.  In the context of the 
self-controlled case series study design, the primary impact of injury under-
ascertainment would be a decrease in sample size and decrease in power to 
estimate the association between stimulant medication and overall injury rates. 
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Medically-attended injuries at hospitals and emergency rooms may reflect different 
types of injury than are seen by GPs.  This would impact the power to estimate the 
association for specific types of injury.  A secondary impact would occur if missed 
injuries were related to the timing of the subsequent recorded injuries or the timing 
the exposure.  This is unlikely but cannot be discounted as a possibility. 
Injury information in THIN did not consistently include the information about the 
severity or circumstances of the injury.  This limited more detailed examination of the 
association between stimulant medication use and injury, i.e. examination of 
intentional vs. unintentional injury events. 
Primary care databases 
The use of data from primary care means that information about the care and 
treatment of ADHD in other settings may be missing.  For example, ADHD 
diagnoses made in other settings and not recorded in THIN may have contributed to 
the large number of children who were excluded from this study because of a lack of 
an ADHD diagnosis prior to medication prescription.  Depending on the 
characteristics of these excluded children, selection bias may have resulted.  
Similarly, unrecorded medications, injuries and other ADHD treatments may have 
affected the research results.  The type and comprehensiveness of data provided in 
this primary care database also limited the study of family, school and environment 
factors.  This limitation affected the range of clinical and child characteristics that 
were examined in association with initial medication persistence, and the control of 
potential time-varying confounders in the self-controlled case series analysis.  
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E. FUTURE RESEARCH 
Future research could build upon the findings of this research and address some 
of the noted limitations.  Firstly, validation of ADHD diagnoses and injury outcomes 
to better assess these research findings and continue inquiry into the treatment and 
outcomes of this population.  Secondly, examination of the association between a 
broader range of child, family, treatment, clinician and health system factors and 
ADHD treatment persistent could help identify children who are persistent with 
ADHD medication, understand the reasons underlying these patterns and aid in the 
design and evaluation of interventions to improve medication use.  Thirdly, the 
results from the self-controlled case series study could be compared with a 
traditional cohort design to assess the benefits of each design in the control of 
confounders that impact the association between stimulant medication and injury 
among children with ADHD.  Lastly, the results of this study should be examined in 
further detail by type and circumstance of injury, as well as within subtype or severity 
of ADHD disease. 
F. CONCLUSIONS 
Most children with ADHD who are treated with medication do not continue on 
with initial treatment beyond 6 months and medication type is associated with 
treatment persistence.  Periods of stimulant use are associated with a decreased 
rate of injuries among children diagnosed with ADHD likely reflecting a decrease in 
risk as a result of the reduction of symptoms by stimulant medication.  Further 
research is required to confirm these associations with the consideration of 
additional factors and among subgroups of children with ADHD. 
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APPENDIX A 
 
Table A.1: ADHD codes used to request a subset of THIN patients* 
 
Read code Description 
1BR..00 Reduced concentration 
1BR0.00 Reduced concentration span 
1BR0.11 Short attention span 
E2E..00 Childhood hyperkinetic syndrome 
E2E..11 Overactive child syndrome 
E2E0.00 Child attention deficit disorder 
E2E0000 Attention deficit without hyperactivity 
E2E0100 Attention deficit with hyperactivity 
E2E0z00 Child attention deficit disorder NOS 
E2E1.00 Hyperkinesis with developmental delay 
E2E2.00 Hyperkinetic conduct disorder 
E2Ey.00 Other hyperkinetic manifestation 
E2Ez.00 Hyperkinetic syndrome NOS 
Eu90.00 [X]Hyperkinetic disorders 
Eu90000 [X]Disturbance of activity and attention 
Eu90011 [X]Attention deficit hyperactivity disorder 
Eu90100 [X]Hyperkinetic conduct disorder 
Eu90111 [X]Hyperkinetic disorder associated with conduct disorder 
Eu90200 [X]Deficits in attention, motor control and perception 
Eu90y00 [X]Other hyperkinetic disorders 
Eu90z00 [X]Hyperkinetic disorder, unspecified 
Eu90z11 [X]Hyperkinetic reaction of childhood or adolescence NOS 
Eu90z12 [X]Hyperkinetic syndrome NOS 
Eu9y700 [X]Attention deficit disorder 
Z7C5100 Unable to concentrate 
Z7C5111 Lack of concentration 
Z7C5300 Reduced concentration span 
Z7C5311 Reduced attention span 
Z7C5312 Short attention span 
Z7C5313 Short concentration span 
ZS9..00 Disorders of attention and motor control 
ZS91.00 Attention deficit disorder 
ZS91.11 ADD - Attention deficit disorder 
ZS91.12 [X]Attention deficit disorder 
ZS93.00 Deficits in attention motor control and perception 
ZS93.11 DAMP - Deficits in attention motor control and perception 
 
*all codes related to attention deficit hyperactivity disorder, attention deficit disorder, hyperkinetic 
disorder and the symptoms of inattention, concentration and hyperactivity 
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Table A.2: ADHD medication types and formulations * 
 
 
Drug code in THIN 
 
 
Medication Type 
 
 
Formulation 
 
 
Strength 
Long acting MPH† 
87474998 ATOMOXETINE caps 60mg 2 
87475998 ATOMOXETINE caps 40mg 2 
87476998 ATOMOXETINE caps 25mg 2 
87477998 ATOMOXETINE caps 18mg 2 
87478998 ATOMOXETINE caps 10mg 2 
87479998 ATOMOXETINE caps 60mg 2 
87480998 ATOMOXETINE caps 40mg 2 
87481998 ATOMOXETINE caps 25mg 2 
87482998 ATOMOXETINE caps 18mg 2 
87483998 ATOMOXETINE caps 10mg 2 
86945998 METHYLPHENIDATE caps 30mg 0 
86946998 METHYLPHENIDATE XL caps 20mg 1 
86947998 METHYLPHENIDATE XL caps 10mg 1 
86948998 METHYLPHENIDATE mr cap 30mg 1 
86949998 METHYLPHENIDATE mr cap 10mg 1 
88229998 METHYLPHENIDATE tablets 10mg 0 
89549998 METHYLPHENIDATE modified 
release tablet 
18mg 1 
90590996 METHYLPHENIDATE tablets 20mg 0 
90590997 METHYLPHENIDATE tablets 10mg 0 
90590998 METHYLPHENIDATE tablets 5mg 0 
91237998 METHYLPHENIDATE XL tablets 36mg 1 
91448996 METHYLPHENIDATE tablets 20mg 0 
91448997 METHYLPHENIDATE tablets 5mg 0 
91448998 METHYLPHENIDATE tablets 10mg 0 
91449998 METHYLPHENIDATE tablets 10mg 0 
91480998 METHYLPHENIDATE XL tablets 18mg 1 
91759998 METHYLPHENIDATE tablets 20mg 0 
91844998 METHYLPHENIDATE modified 
release 
capsules 
20mg 1 
92102998 METHYLPHENIDATE tablets 5mg 0 
92441998 METHYLPHENIDATE modified 
release tablet 
36mg 1 
94309998 METHYLPHENIDATE XL capsules 20mg 1 
94837990 METHYLPHENIDATE Tabs 10mg 0 
94905990 METHYLPHENIDATE Tabs 20mg 0 
94906990 METHYLPHENIDATE Tabs 10mg 0 
94907990 METHYLPHENIDATE Tabs 5mg 0 
95064990 METHYLPHENIDATE tablets 20mg 0 
95065990 METHYLPHENIDATE tablets 10mg 0 
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Table A.2: ADHD medication types and formulations continued 
 
* These drug types and formulations were used to request a subset of THIN data. Research 
regarding Specific Aim 1 used all of these drug types and formulations. Research regarding Specific 
Aim 2 excluded atomoxetine types and formulations.  
 
 
Drug code in 
THIN 
 
 
Medication Type 
 
 
Formulation 
 
 
Strength 
Long acting MPH† 
95066990 METHYLPHENIDATE tablets 5mg 0 
95549992 METHYLPHENIDATE 
HYDROCHLORIDE 
TAB 25mg 0 
96421996 DEXAMFETAMINE+ 
AMPHETAMINE 
capsules 10mg + 
10mg 
2 
96421997 DEXAMFETAMINE+ 
AMPHETAMINE 
capsules 6.25mg 
+ 
6.25mg 
2 
96421998 DEXAMFETAMINE+ 
AMPHETAMINE 
capsules 3.75mg 
+ 
3.75mg 
2 
96422998 DEXAMFETAMINE tablets 5mg 2 
98291996 DEXAMFETAMINE+ 
AMPHETAMINE 
capsules 20mg 2 
98291997 DEXAMFETAMINE+ 
AMPHETAMINE 
capsules 12.5mg 2 
98291998 DEXAMFETAMINE+ 
AMPHETAMINE 
capsules 7.5mg 2 
99765998 DEXAMFETAMINE tablets 5mg  
94312990 DEXAMFETAMINE oral liq 1mg/ml 2 
86933998 DEXAMFETAMINE oral liq 1mg/ml 2 
86042998 DEXAMFETAMINE 
SULPHATE 
Cap 15mg 2 
86043998 DEXAMFETAMINE 
SULPHATE 
MR cap 15mg 2 
93857992 DEXAMPHETAMINE 
SULPHATE 
TAB 0 2 
94910992 DEXAMPHETAMINE 
SULPHATE 
TAB 2.5mg 2 
96180992 DEXAMPHETAMINE 
SULPHATE 
CAP 15mg 2 
97253992 DEXAMPHETAMINE 
SULPHATE 
SPA 15mg 2 
97254992 DEXAMPHETAMINE 
SULPHATE 
TAB 5mg 2 
97255992 DEXAMPHETAMINE 
SULPHATE 
CAP 10mg 2 
96633992 DEXAMPHETAMINE 
SULPHATE/AMPHETAMINE 
CAP 7.5mg 2 
97252992 DEXAMPHETAMINE 
SULPHATE/AMPHETAMINE 
CAP 20mg 2 
97260992 DEXTROAMPHETAMINE TAB 5mg 2 
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† MPH, methylphenidate, 1 = long-acting methylphenidate, 0= standard formulation methylphenidate, 
2= neither long-acting or standard formulation methylphenidate 
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APPENDIX B 
 
Table B.1: Read codes used to define ADHD diagnosis 
 
Used to 
define 
ADHD Read code Description 
 
 
Frequency * 
Yes Eu9y700 [X]Attention deficit disorder  
Yes ZS91.12 [X]Attention deficit disorder  
Yes Eu90011 [X]Attention deficit hyperactivity disorder 1593 
Yes Eu90100 [X]Hyperkinetic conduct disorder  
Yes Eu90111 
[X]Hyperkinetic disorder associated with conduct 
disorder 
 
Yes Eu90z00 [X]Hyperkinetic disorder, unspecified  
Yes Eu90.00 [X]Hyperkinetic disorders  
Yes Eu90z12 [X]Hyperkinetic syndrome NOS  
Yes Eu90y00 [X]Other hyperkinetic disorders  
Yes ZS91.11 ADD - Attention deficit disorder  
Yes ZS91.00 Attention deficit disorder  
Yes E2E0100 Attention deficit with hyperactivity  
Yes E2E0000 Attention deficit without hyperactivity  
Yes E2E0.00 Child attention deficit disorder 869 
Yes E2E0z00 Child attention deficit disorder NOS  
Yes E2E..00 Childhood hyperkinetic syndrome 690 
Yes E2E2.00 Hyperkinetic conduct disorder  
Yes E2Ez.00 Hyperkinetic syndrome NOS  
Yes 1BR..00 Reduced concentration 129 
Yes 1BR0.11 Short attention span 76 
Yes Z7C5312 Short attention span  
  
EXCLUDED CODES  
No Z7C5313 Short concentration span  
No Z7C5100 Unable to concentrate  
No Eu90200 [X]Deficits in attention, motor control and perception  
No Eu90000 [X]Disturbance of activity and attention  
No Eu90z11 
[X]Hyperkinetic reaction of childhood or adolescence 
NOS 
 
No ZS93.11 
DAMP - Deficits in attention motor control and 
perception 
 
No ZS93.00 Deficits in attention motor control and perception  
No ZS9..00 Disorders of attention and motor control  
No E2E1.00 Hyperkinesis with developmental delay  
No Z7C5111 Lack of concentration  
No E2Ey.00 Other hyperkinetic manifestation  
No E2E..11 Overactive child syndrome  
No Z7C5311 Reduced attention span  
No 1BR0.00 Reduced concentration span  
No Z7C5300 Reduced concentration span  
 
* only the frequencies of the 5 most frequent ADHD-related codes (on the initial diagnosis day) 
among the children in the overall study group are listed 
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APPENDIX C 
 
Table C.1: Inclusion and exclusion keywords, and resulting Read codes* used to define an 
anxiety disorder. 
 
Inclusion 
Keywords 
Exclusion keywords Read code 
 
Description 
‘anxiety’ 
‘anxious’ 
‘affective disorder’ 
‘affective illness’ 
‘E2D0100’ † 
‘mother’ 
‘score’ 
‘guided’ 
‘separation anxiety’ 
'anxiety with depression’ 
 
1466.00 
E202.12  
E200000 
2258.00 
1B13.00 
1B13.11  
E200.00 
H/O: Anxiety state  
Phobic anxiety 
Anxiety state unspecified  
O/E - Anxious 
Anxiousness 
Anxiousness- symptom 
Anxiety states 
 
*only Read codes contained in records that occurred on the same date as initial diagnosis date are 
presented 
† E2D0100=childhood and adolescent fearfulness disturbance. This Read code added to list based 
on review of Read codes in subchapters related to anxiety codes  
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Table C.2: Inclusion and exclusion keywords, and resulting Read codes* used to define a 
conduct disorder. 
 
Inclusion 
keywords 
Exclusion keywords Read 
code 
 
Description 
‘conduct’ 
‘oppositional’ 
‘defiant’ 
‘disruptive’ 
 
 
‘conductance’ 
‘conductivity’ 
‘hearing’ 
‘conducting’ 
‘conduction’ 
‘conductive’ 
E2C2.00  
E2C..00 
E2E2.00 
E2C0.00 
Socialised conduct disorder  
Disturbance of conduct  
Hyperkinetic conduct disorder  
Aggressive unsocial conduct disorder 
 
 
*only Read codes contained in records that occurred on the same date as initial diagnosis date are 
presented 
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Table C.3: Inclusion and exclusion keywords, and resulting Read codes* used to define a 
depression disorder. 
 
Inclusion 
keywords 
Exclusion keywords Read code 
 
Description 
‘depression’ 
‘depressed’ 
‘depressive’ 
‘dysthymia’ 
‘unipolar’ 
‘affective disorder’ 
‘affective illness’ 
 
‘scale’ 
‘screen’ 
‘review’ 
‘beck’ 
‘annual’ 
‘register’ 
‘postnatal’ 
‘resolved’ 
‘reporting’ 
‘quality’ 
‘guided’ 
‘management’ 
 
E112.14 
E112.11 
E291.00  
E2B1.00 
E113200 
 
E135.00  
E112100 
 
E112200 
 
E204.00 
 
2257.00  
E112.00 
1465.00 
E113.11  
 
E112.13 
 
1B1U.00 
E200300 
E2B..00 
1B17.00 
1BT..00 
1B17.11 
Endogenous Depression 
Agitated Depression 
Prolonged Depressive Reaction 
Chronic Depression 
Recurrent major depressive 
episodes, moderate 
Agitated Depression 
Single major depressive 
episode, mild 
Single major depressive 
episode, moderate 
Neurotic depression reactive 
type 
O/E- depressed 
Single major depressive episode 
H/O: Depression 
Endogenous  
Depression-recurrent 
Endogenous depression first 
episode 
Symptoms of depression 
Anxiety with depression 
Depressive disorder nec 
Depressed 
Depressive Mood 
C/O- Feeling depressed 
 
 *only Read codes contained in records that occurred on the same date as initial diagnosis date are 
presented 
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APPENDIX D 
 
Table D.1: Relevant specialist-related Read codes with frequency >5 among initial diagnosis 
day records 
 
Frequency* Read code Description 
7 9N3D.00 Letter received 
7 9N36.11 Letter from consultant 
7 8H42.00 Referral to paediatrician 
11 ZL9D.00 Seen by psychiatrist 
12 8HHR.00 Referral to child and adolescent psychiatry service 
14 9ND5.00 Consultant letter from 
14 6A1..00 Patient reviewed at hospital 
16 ZL97.00 Seen by paediatrician 
16 8H49.00 Psychiatric referral 
18 9NC1.00 Letter sent to consultant 
21 9N33.11 Letter encounter 
22 8HD..00 Refer to hospital 
31 ZL97100 Seen by community paediatrician 
37 ZL9D100 Seen by child and adolescent psychiatrist 
38 9N1A.00 Seen in hospital out-pat 
44 9N0T.00 Seen in child psychology clinic 
68 9N1T.00 Seen in psychiatry clinic 
68 9N1T.00 Out of hours consultation at surgery  
185 9N36.00 Letter from specialist 
372 9N1V.00 Seen in paediatric clinic 
* among all medical records from the same day as the initial diagnosis of ADHD 
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Table D.2: Relevant ‘source’ variable values 
 
Value Description 
F Patient requested referral 
L Hospital letter 
O Doctor referral to Other    
R Doctor referral to outpatients   
I Patient requested referral to outpatients 
J 3rd Party referral 
K 3rd Party referral to outpatients 
T Doctor referral to Direct access 
1 Referral to outpatients    
2 Referral to other 
6 Doctor referral 
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APPENDIX E 
 
Determination of death 
From records of the overall study group, records with either of the following 
characteristics were selected: 
i) In ‘patient’ data, registration information (‘regstat’ variable=99) indicating 
death 
ii) a Read code that may indicate a person has died either in ‘medical records’ 
or ‘additional health data’ records*  
The 78 resulting records about 30 unique patients were manually reviewed. Patients 
were considered to have died if i) registration information indicated death or ii) if the 
registration information did not indicate death, the additional health information 
included a death date and there were no subsequent medical or therapy records 
after the death date (other than post mortem, or death administrative Read codes). 
Using this process for the 4234 overall study group, 7 children were determined to 
have died during the study period. 
 
 
 
 
*an exhaustive list of 235 Read codes that may indicate death have been previously 
selected by THIN researchers is included in the table below. 
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Table E.1: Read codes that may indicate death 
 
 
 
 
 
 
22J..00 9414.00 949..13 Q486.00 T402.00 TK03.00 TKx1.00 
22J..11 941Z.00 949..14 Q48y600 T403.00 TK04.00 TKx2.00 
22J..12 942..00' 9491.00 Q48y700 T404.00 TK05.00 TKx4.00 
22J..13 943..00 9492.00 Q4z..11 T405.00 TK06.00 TKx5.00 
22J..14 9431.00 9493.00 Q4z..12 T406.00 TK07.00 TKx7.00 
22J1.00 9432.00 9494.00 Q4z..13 TF0..00 TK08.00 TKxy.00 
22J2.00 9433.00 9495.00 Q4z..14 TF01.00 TK0z.00 TKxz.00 
22J3.00 943Z.00 9496.00 R2...12 TF01000 TK1..00 TKz..00 
22J4.00 944..00 9497.00 R21..00 TF01200 TK10.00 TL...00' 
22J5.00 9441.00 9498.00 R210.00 TF02.00 TK11.00 TL0..00 
22J6.00 9442.00 9499.00 R210000 TF02100 TK1z.00 TL4..00 
22J7.00 9443.00 949A.00 R210100 TF02300 TK2..00 TL9..00 
22JZ.00 944Z.00 949B.00 R210200 TF02400 TK20.00 TLxz000 
236..12 945..00 949C.00 R210z00 TF02600 TK21.00 TLxz200 
4K9..00 9451.00 949Z.00 R211.00 TF03000 TK3..00 TLxz400 
4K91.00 9452.00 94A..00 R212.00 TF03100 TK30.00 TP52.00 
4K92.00 9453.00 94A..11 R212000 TF03300 TK31.00 U090.00 
4K94.00 945Z.00 94B..00 R212100 TF04.00 TK3y.00 U13..00 
4K95.00 946..00 94B..11 R212z00 TF0y.00 TK3z.00 U131.00 
4K96.00 947..00 94C..00 R213.00 TF0y000 TK4..00 U132.00 
4K9Z.00 947..11 94C0.00 R213000 TF0y100 TK5..00 U132000 
7L1M000 9472.00 94D..00 R213100 TF0yz00 TK51.00 U135.00 
8HG..00 9473.00 94E..00 R213z00 TF0z.00 TK52.00 U2...13 
8HG..11 947Z.00 94F..00 R21z.00 TG30500 TK6..00 U22..00 
9134.00 948..00 94Z..00 RyuC.00 TGyz400 TK60.00 U3...12 
9134.11 948..11 G575100 RyuC000 TK...00 TK61.00 U3...13 
9134.12 9481.00 L39A.00 SN41300 TK...14 TK6z.00 U42..00 
9234.00 9482.00 L39B.00 T053.00 TK0..00 TK7..00 ZV68011 
94...00' 9483.00 L39X.00 T053100 TK00.00 TK70.00 ZX15.00' 
94...11 '9484.00 Lyu7500 T053200 TK01.00 TK71.00 941..11 
941..00 948Z.00 Q016.00 T053z00 TK01000 TK72.00 944..11 
9411.00 949..00 Q016.11 T0y0.00 TK01100 TK7z.00  
9412.00 949..11 Q210.00 T0y0200 TK01300 TKx..00  
9413.00 949..12 Q211.00 T0y0z00 TK02.00 TKx0000  
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APPENDIX F: 
  
Sensitivity analyses varying the grace period used in analysis of medication 
persistence (RESULTS CHAPTER V) 
The multivariate analysis for Results Chapter V was repeated using a 60 and 90 
day grace period.  The results are shown in Table F.1.  Varying the grace period to 
60 or 90 days changed the proportion of children who were persistence (to 56.9% 
and 68.5% respectively) but did not substantially change the result of which 
predictors were associated with persistence.  
In addition, age group (15-18 years) was associated with less persistence, 
which was more clearly apparent when a 60 or 90 day grace period was used. 
This finding is consistent with the literature.  Younger children have better 
adherence to psychotropic medication than older children, in part because parents 
have a greater role in influencing medication use for younger children and 
adolescents may be responsible for their own medication.[73]  The discontinuation of 
medication among adolescents who initiate medication at age 15 often occurred 
within a year.  This discontinuation was greater than expected, given known age-
related decreases in symptoms, suggesting that this group may be prematurely 
discontinuing medication treatment.  A UK qualitative study suggested that difficulty 
in transitioning to adult services may contribute to medication discontinuation.[129] 
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Table F.1: Selected predictors of initial treatment course length of at least 6 months among children with ADHD in the UK (n=1314) 
using 30, 60 and 90 day grace periods 
 
 
N=1314 
n (%)* 
Risk 
Ratio† 
95% 
Confidence 
IntervaI 
(CI) 
N=1314 
n (%)* 
Risk 
Ratio† 
95% CI N=1314 
n (%)* 
Risk 
Ratio† 
95% CI 
 30 day 
grace 
period 
  60 day 
grace 
period 
  90 day 
grace 
period 
  
 
         
Overall  464 (35.3)   767 (56.9)   865 (68.5)   
Gender 
         
  Female 58 (30.1) 0.9 0.7, 1.1 91 (47.2) 0.8 0.7, 0.9 118 (61.1) 0.9  0.8, 1.0 
  Male 406 (36.2) 1.0 Reference‡ 656 (58.5) 1.0 Reference 783 (69.9) 1.0 Reference 
Age group at 
diagnosis (years) 
         
  1-5 42 (34.7) 1.0 0.6, 1.7 66 (54.5) 0.9 0.8, 1.1 77 (63.6) 0.9 0.8, 1.0 
  6-9 232 (36.0) 1.0 Reference 381 (59.2) 1.0 Reference 465 (72.2) 1.0 Reference 
 10-14 178 (35.5) 0.8 0.7, 1.0 280 (55.8) 0.9 0.8, 1.0 334 (66.5) 0.9 0.8, 1.0 
 15-18 12 (25.5) 0.7 0.4, 1.2 20 (42.6) 0.6 0.5, 0.9 25 (53.2) 0.7 0.5, 0.9 
Year of diagnosis 
         
1993 - 2001 78 (25.2) 1.0 Reference 146 (47.3) 1.0 Reference 194 (62.8) 1.0 Reference 
 2002 - 2006 386 (38.4) 1.4 1.1, 1.7 601 (59.8) 1.4 1.1, 1.4 707 (70.3) 1.1 1.0, 1.3 
Socioeconomic status 
(Townsend Index, 
quintile) 
         
   1 88 (28.0) 1.0 0.8, 1.2 130 (59.1) 1.0 0.9, 1.1 149 (67.7) 0.9 0.9, 1.1 
   2 49 (32.3) 0.8 0.6, 1.0 87 (49.7) 0.9 0.8, 1.1 113 (64.6) 0.9 0.8, 1.1 
   3 87 (32.3) 0.9 0.7, 1.1 159 (59.1) 1.0 0.9, 1.2 190 (70.6) 1.0 0.9, 1.1 
   4 112 (36.6) 1.0 0.8, 1.2 172 (56.2) 1.0 0.9, 1.1 205 (67.0) 0.9 0.9, 1.1 
   5 100 (38.9) 1. Reference 152 (59.1) 1.0 Reference 184 (71.6) 1.0 Reference 
Comorbidities 
         
   Anxiety disorders 5 (55.6) 1.8 0.7, 4.6 4 (44.4) 0.9 0.5, 1.7 5 (55.6) 0.9 0.6, 1.6 
   Depression disorders 1 (20.0) 0.9 0.2, 4.2 3 (60.0) 0.6 0.4, 1.5 3 (60.0) 0.7 0.3, 1.4 
   Conduct disorders 1 (16.7) 1.0 0.1, 2.1 3 (50.0) 1.6 0.7, 3.8 3 (50.0) 1.3 0.6, 2.9 
   No comorbidity 457 (35.3) 1. Reference 737 (57.0) 1.0 Reference 890 (68.8) 1.0 Reference 
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Table F.1: Selected predictors of initial treatment course length of at least 6 months among children with ADHD in the UK (n=1314) 
Continued 
 
N=1314 
n (%)* 
Risk 
Ratio† 
95% 
Confidence 
IntervaI 
(CI) 
N=1314 
n (%)* 
Risk 
Ratio† 
95% CI N=1314 
n (%)* 
Risk 
Ratio† 
95% CI 
Specialist contact on 
index day 
         
   Yes 186 (33.9) 1.0 0.8, 1.1 311 (56.6) 1.0 0.9, 1.1 380 (69.2) 1.0 0.9, 1.1 
   No 278 (36.3) 1. Reference 436 (57.0) 1.0 Reference 521 (68.1) 1.0 Reference 
First drug type 
         
   Dexamphetamine 7 (33.3) 1.0 0.6, 1.9 14 (66.7) 1.2 0.9, 1.7 14 (66.7) 1.0 0.7, 1.4 
   Atomoxetine 23 (41.4) 1.3 0.9, 1.7 29 (51.8) 1.0 0.8, 1.3 33 (58.9) 0.9 0.7, 1.2 
   Long-acting MPH § 144 (41.6) 1.2 1.1, 1.4 215 (62.1) 1.1 1.0, 1.3 241 (69.7) 1.0 1.0, 1.1 
   MPH 290 (32.5) 1.0 Reference 489 (54.9) 1.0 Reference 613 (68.8)   
Time from diagnosis to 
medication initiation 
         
   0 94 (36.4) 1.0 Reference 149 (57.8) 1.0 Reference 173 (667.1) 1.0 Reference 
   1-30 days 95 (40.6) 1.1 0.9, 1.4 161 (68.8) 1.2 1.0, 1.4 187 (79.9) 1.2 1.1, 1.3 
   31-60 days 51 (39.5) 1.0 0.7, 1.3 82 (63.6) 1.0 0.9, 1.2 93 (72.1) 1.0 0.9, 1.2 
   61-90 days 35 (38.8) 1.0 0.7, 1.3 53 (58.9) 1.0 0.8, 1.2 60 (66.7) 1.0 0.8, 1.2 
   91-120 days 32 (36.8) 1.0 0.7, 1.3 48 (55.2) 0.9 0.8, 1.2 58 (66.7) 1.0 0.9, 1.2 
   121-180 days 48 (36.1) 0.9 0.7, 1.1 76 (57.1) 0.9 0.8, 1.2 97 (72.9) 1.0 0.9, 1.2 
   181-365 days 66 (31.4) 0.9 0.7, 1.1 102 (48.6) 0.8 0.7, 1.0 131 (62.4) 0.9 0.8, 1.1 
   1-2 years 43 (24.9) 0.7 0.5, 0.9 76 (42.9) 0.8 0.6, 0.9 102 (59.0) 0.9 0.7, 1.0 
* Proportion of children within each category who were persistent with initial medication treatment for at least 6 months. 
† Adjusted for all other factors in the table.  A risk ratio greater than 1 indicates an increased ‘risk’ of continuing initial treatment beyond 6 months 
as compared with the reference group. 
‡ Reference=reference category 
§ MPH, methylphenidate 
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APPENDIX G:  
 
Comparing the results of the self-controlled case series (SCCS) to other 
cohort analyses: 
OBJECTIVE: 
To examine if the exclusion of potential study participants that is required when 
using the SCCS method has an effect on estimates of the association between 
stimulant medication and injury, in particular, the exclusion of uninjured children and 
children with ADHD who have not been treated (never-treated).  
METHODS: 
Results of the SCCS were compared to the results of two other cohort groups 
from the same administrative database. 
Study groups: 
The SCCS compared injury rates during treated and untreated time among 328 
children who have been both treated with stimulant medication and injured.  
Cohort 1 included these 328 children and an additional 1432 children who had 
been treated with stimulant medication but had not been injured (total n=1760).  
Cohort 2 included the above children and an additional 2223 children with 
ADHD who had never been treated with stimulant medication (total n=3983).  
Thus, subjects in the SCCS were a subset of the subjects in Cohort 1 and 
subjects in Cohort 1 were a subset of the subjects in Cohort 2. 
Children treated with non-stimulants were excluded from these analyses. 
The exposure (stimulant medication), outcome (medically attended injury) and 
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follow-up time in each analysis was defined as in the SCCS analysis (exposure: at 
least 1 prescription for stimulant medication, a 30 grace period to determine the end 
of a treatment period, outcome: the first ever injury occurring in the study period, 
follow-up from the day of diagnosis to the earliest of the death date, transfer date, 
19th birthday, or last collection date for the GP practice).  Note that 'age at initial 
medication' could not be defined for all subjects in Cohort 2 (since not all included 
children were treated with medication).  Therefore, we elected to present an analysis 
of 'age at diagnosis' instead.  Also, for the subgroup analysis by initial medication 
type in Cohort 2, never-treated children contributed to the untreated person-time 
only.  Their presence is reflected in the “n”s in Table G.2. 
Analysis: 
The person-time for each study group was organized into exposure/covariate 
categories.  Whereas the SCCS used a conditional Poisson model (stratified by 
individual) the analyses of Cohort 1 and 2 used a Poisson model without 
stratification by individual to estimate incident rate ratios, 95% confidence intervals 
and confidence limit ratios. 
The SCCS required adjustment for only time-varying covariates (age group, 
season).  The analyses of Cohort 1 and 2 adjusted all estimates for both time-
varying covariates (age group, season) as well as three fixed covariates measured 
at baseline: socio-economic status (SES), gender, presence of comorbidities.  
RESULTS 
In comparison to the SCCS study group, Cohort 1 added treated and untreated 
person-time from 1432 treated children with ADHD.  No new injuries were added, 
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since, by definition, all injured children in Cohort 1 were included in the SCCS (Table 
G.1). 
In comparison to the SCCS study group and Cohort 1, Cohort 2 (n=3983) 
included the above 1432 children as well as an additional 2223 never-treated 
children with ADHD (both injured and uninjured).  The number of injury events that 
occurred during unexposed person-time as well as total untreated person-time 
increased in Cohort 2 in comparison with Cohort 1 (Table G.1) 
Crude estimates (Table G.1) and the overall adjusted estimates (Table G.2) of 
the association between stimulant medication and injury for the three study groups 
are similar.  The Cohort 1 and Cohort 2 overall estimates have slightly greater 
precision than the SCCS estimates (See CLR column Table G.2). 
The estimates for girls are more precise in the Cohort analyses as compared to 
the SCCS, and although the point estimates decrease suggesting a protective effect 
of medication among girls, these conclusions are still limited by low precision.  The 
estimates for boys however, are consistently protective across the three analyses. 
Age estimates appear protective in oldest age group in the Cohort 1 and 2 
analyses as compared to the SCCS, however the precision of all estimates for the 
15-18 year group is low (SCCS: IRR=0.85; 95%CI (0.28, 2.56) CLR: 9.14, Cohort 1 
IRR=0.49; 95%CI:0.18, 1.31; CLR:7.12, Cohort 2 IRR=0.39; 95%CI:0.09, 1.64; CLR: 
17.71). 
In terms of medication type, both MPH and long-acting MPH are protective in 
all three analyses.  
As in the SCCS analysis, adjustment for time-varying covariates did not 
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substantially change the main estimates in Cohort 1 and Cohort 2.  The chosen 
time-varying and fixed covariates that were adjusted for in the Cohort 1 and 2 
analyses also did not substantially change the main estimates. 
DISCUSSION 
Overall, the main estimates for the association between stimulant medication 
and injury rates were very similar across the three groups (SCCS, Cohort 1 and 
Cohort 2).  The estimates were increasingly precise as the sample size increases, 
however, the gain in precision was modest. 
The rationale for the use of the SCCS was that traditional comparisons 
between treated and untreated children could potentially be confounded by inter-
child differences that would be challenging to effectively control for, using 
administrative data.  The analysis of Cohort 1 would thus indicate if the exclusion of 
uninjured (and treated) children affected the SCCS results.  The analysis of Cohort 2 
would indicate if the exclusion of never-treated children affected the SCCS results. 
Example of a potentially confounding difference between treated and never-treated 
children are ADHD severity (i.e. the children with more severe ADHD are more likely 
to receive medication and are also more likely to be injured) or parental healthcare-
seeking behavior (parents with greater healthcare-seeking behavior would be more 
likely to receive medication for their children and be more likely supervise children 
resulting in fewer injuries). 
If there were a large difference between the children being compared in the 
analyses, results may have differed.  For example, if the injury rates during the 
treated and untreated person-time contributed by the additional 1432 children added 
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to make Cohort 1 were substantially different than the injury rates in the SCCS, the 
rate ratios may have differed. 
Similarly, the addition of the untreated person-time of the 2223 never-treated 
children to make Cohort 2 did not affect the results.  This suggests that injury rates 
of treated children while untreated are similar to injury rates of never-treated children 
and that any expected differences between the groups do not affect the medication-
injury association substantially. 
In conclusion, for the study of stimulant medication and injury in this setting, the 
use of the SCCS design was not as advantageous as originally perceived, since the 
traditional cohort analyses yielded similar results with slightly greater precision.  
However, if more complete cohort data was not available or if primary data collection 
was necessary, the SCCS would be a reasonable method to estimate this 
association.  Furthermore, in other research studies, it is very possible that the 
covariates typically obtained from administrative databases may not be sufficiently 
detailed to obtain unbiased estimates by any means other than the SCCS method. 
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Table G.1: Description of injuries and follow-up time by gender (Self-controlled case series 
(SCCS), n=328. Cohort 1, n=1760, Cohort 2, n=3983) 
 
* Treated time - follow-up time (child-years) with exposure to stimulant medication  
† Untreated time – follow-up time (child-years) without exposure to stimulant medication 
‡ As SCCS estimates are within-individual comparison, crude estimates may not be calculated 
directly using these person-time totals. 
 
Group N 
children 
Injuries 
n (%) 
Injuries 
on 
treatment* 
Total 
treatment 
time 
(child-
years) 
Injuries 
while 
untreated 
Total 
untreated 
time 
(child-
years)† 
Crude 
rate 
ratio 
95%CI 
SCCS 328 328  139 885.4 189 1041.8 0.70‡ 0.53, 
0.94 
Gender 
        
Male  285  117 778.8 168 934.6 0.67‡ 0.59, 
0.92 
Female  43  22 106.6 21 107.2 0.92‡ 0.42, 
1.99 
         
Cohort 
1  
1760 328  139 3608.3 189 3619.9 0.72 0.56, 
0.86 
Gender 
        
Male 1506  285 117 3134.0 168 3052.2 0.69 0.53, 
0.84 
Female 254  43  22 484.0 21 433.4 0.97 0.52, 
1.78 
         
Cohort 
2  
3983 742 139 3598.3 603 11092.6 0.71 0.59, 
0.85 
Gender 
        
Male 3327 621 117 3134.0 504 9329.7 0.69 0.57, 
0.85 
Female 656 121 22 484.0 99 1748.8 0.80 0.51, 
1.27 
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Table G.2: Subgroup analyses for the SCCS and cohort groups 
Original analysis: SCCS Injured 
(n) 
Adjusted IRR 
(95%CI)* 
CLR† 
All stimulants 328 0.70 (0.52, 0.93) 1.79 
Gender 
   
Boys 285 0.66 (0.48, 0.91) 1.90 
Girls 43 0.98 (0.44, 2.10) 4.77 
Age at initial prescription 
(years) 
   
1-5 10 0.52 (0.11, 2.48)  22.5 
6-9 151 0.78 (0.52, 1.18) 2.27 
10-14 140 0.62 (0.39, 0.97) 2.49 
15-18 27 0.85 (0.28, 2.56) 9.14 
Initial medication type 
   
MPH  252 0.72 (0.52, 1.01) 1.94 
Long-acting MPH  71 0.71 (0.37, 1.39) 3.76 
Dexamphetamine 5 0.06 (0.00, 6.93) >1000 
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*SCCS estimates adjusted for time-varying covariates (age group and season), Cohort 1 and 2 
estimates adjusted for time-varying covariates (age group and season) and fixed covariates 
(presence of comorbidities, socio-economic status (SES), gender)  
Age group estimates not adjusted for age, gender estimates not adjusted for gender 
† CLR, confidence limit ratio: upper confidence limit/lower confidence limit 
 
TABLE G.2 continued 
Cohort 1: Including 
non-injured/treated  
Total Injured 
(n) 
Adjusted IRR 
(95%CI) 
CLR† 
All stimulants 1760 328 0.72 (0.57, 0.91) 1.58 
Gender 
    
Boys 1506 285 0.69 (0.54, 0.89) 1.63 
Girls 254 43 0.94 (0.51, 1.75) 3.46 
Age at initial 
prescription (years) 
    
1-5 78 10 1.20 (0.29, 5.03) 17.39 
6-9 793 151 0.86 (0.62, 1.19) 1.93 
10-14 771 140 0.66 (0.46, 0.94) 2.05 
15-18 118 27 0.49 (0.18, 1.31) 7.12 
Initial medication type 
    
MPH  1104 252 0.72 (0.55, 0.93) 1.69 
Long-acting MPH  625 71 0.75 (0.47, 1.20) 2.57 
Dexamphetamine 31 5 0.83 (0.06, 10.85) 169.5 
Cohort 2: Including 
never-treated 
Total Injured 
(n) 
Adjusted IRR 
(95%CI) 
CLR† 
All stimulants 3983 742 0.71 (0.59, 0.86) 1.44 
Gender 
    
Boys 3327 621 0.70 (0.57, 0.86) 1.51 
Girls 656 121 0.82 (0.51, 1.33) 2.60 
Age at initial 
diagnosis (years) 
    
1-5 635 122 0.62 (0.33, 1.15) 3.48 
6-9 1742 350 0.76 (0.59, 0.98) 1.66 
10-14 1310 233 0.70 (0.50, 0.98) 1.96 
15-18 296 37 0.39 (0.09, 1.64) 17.71 
Initial medication type 
    
MPH + 2223 never-
treated  
3327 663 0.73 (0.59, 0.90) 1.51 
Long-acting MPH + 
2223 never-treated  
2848 482 0.68 (0.47, 0.99) 2.10 
Dexamphetamine + 
2223 never-treated 
2228 416 0.38 (0.05, 2.70) 51.0 
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APPENDIX H 
 
Table H.1: Self-controlled case series analyses: adjusted incident rate ratios (IRR) (95%CI), 
comparisons to untreated period prior to medication initiation 
 
 
*IRR, incident rate ratio; CI, confidence interval.  The IRR estimates the relative rate of injury 
comparing treated periods to untreated periods.  All estimates are self-controlled and additionally 
adjusted for age group and season 
 
Table H.1 presents rate ratios that compare treated and untreated periods to the 
period of time between diagnosis and initial treatment.  Rates of injury during 
untreated periods were lower after medication initiation than before medication 
initiation (IRR= 0.60; 95%CI: 0.39, 0.92). 
 
 
  
Adjusted* IRR (95%CI) 
Treated time vs. untreated time 0.70 (0.52, 0.93) 
Exposed to medication Time period 
 
No Post diagnosis, pre-initial medication course  1.00 (reference) 
Yes First 30 days of any medication course  0.46 (0.26, 0.81) 
Yes >30 days of any medication course  0.51 (0.34, 0.77) 
No Between or after medication courses  0.60 (0.39, 0.92) 
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